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Résumé 
 
Introduction: L'arthrose est caractérisée par une destruction progressive du cartilage, une 
inflammation synoviale, et un remodelage de l’os sous-chondral avec une production 
excessive des médiateurs inflammatoires et cataboliques. Nous avons démontré que le niveau 
du 4-hydroxynonénal (4-HNE), un produit de la peroxydation lipidique, est augmenté dans le 
cartilage humain arthrosique sans qu’on sache le mécanisme exacte impliqué dans 
l’augmentation de cette molécule. Des données de la littérature indiquent que l’accumulation 
du HNE est contrôlée par l’action de la glutathione S-transférase A4-4 (GSTA4-4), une 
enzyme impliquée dans la  détoxification du HNE. Au niveau transcriptionel, l’expression de 
cette enzyme est régulée par la transactivation du facteur de transcription Nrf2. Objectif: 
L’objectif de cette étude vise à démontrer que l’augmentation du HNE dans le cartilage 
arthrosique est attribuée, en partie, à l’altération de l’expression de la GSTA4-4 et de Nrf2. 
Méthode: Le niveau d’expression de la GSTA4-4 et de Nrf2 a été mesurée par Western blot et 
par PCR en temps réel dans le cartilage humain arthrosique et dans le cartilage provenant des 
souris atteintes d’arthrose. Pour démontrer le rôle du Nrf2 dans l’arthrose, les chondrocytes 
humains arthrosiques ont été traités par l’interleukine 1beta (IL-1) ou par le H2O2 en 
présence ou en absence des activateurs du Nrf2 tels que le Protandim®, AI, et du 6-Gingérol. 
Par ailleurs, les chondrocytes ont été transfectés par un vecteur d’expression de Nrf2 puis 
traités par l’IL-. En utilisant le modèle d’arthrose chez la souris, les animaux ont été traités 
par voie orale de 10 mg/kg/jour de Protandim® pendant 8 semaines. Résultats: Nous avons 
observé une diminution significative de l’expression de la GSTA4-4 et de Nrf2 dans le 
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cartilage humain et murin arthrosique. L'activation de Nrf2 bloque la stimulation  de la 
métalloprotéinase-13 (MMP-13), la prostaglandine E2 (PGE2) et de l'oxyde nitrique (NO) par 
l’IL-1. En outre, nous avons montré que l'activation Nrf2 protège les cellules contre la mort 
cellulaire induite par H2O2. Fait intéressant, l'administration orale de Protandim® réduit la 
production du HNE par l'intermédiaire de l’activation de la GSTA4. Nous avons démontré que 
le niveau d’expression de la GSTA4-4 et de Nrf2 diminue dans le cartilage provenant des 
patients et des souris atteints d’arthrose. De plus, la surexpression de ce facteur nucléaire Nrf2 
empêche la production du HNE et la MMP-13 et l’inactivation de la GSTA4-4. Dans notre 
modèle expérimental d’arthrose induite par déstabilisation du ménisque médial chez la souris, 
nous avons trouvé que l'administration orale de Protandim® à 10 mg / kg / jour réduit les 
lésions du cartilage. Conclusion: Cette étude est de la première pour démontrer le rôle 
physiopathologique du Nrf2 in vitro et in vivo. Nos résultats démontrent que l’activation du 
Nrf2 est essentielle afin de maintenir l’expression de la GSTA4-4 et de réduire le niveau du 
HNE. Le fait que les activateurs du Nrf2 abolissent la production de la HNE et aussi un certain 
nombre de facteurs connus pour être impliqués dans la pathogenèse de l’arthrose les rend des 
agents cliniquement utiles pour la prévention de la maladie. 
 
Mots-clés : Arthrose, cartilage, hydroxynonénal, glutathione S-transferase, Nrf2, catabolisme, 
inflammation. 
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Summary 
 
Background: Osteoarthritis (OA) is characterized by progressive cartilage destruction, 
synovial inflammation, and subchondral bone remodelling with increased inflammatory and 
catabolic responses. Elevated levels of oxidative stress lead to the accumulation of reactive 
oxygen species and subsequently the production of lipid-peroxidation products (LPO). The 
toxic aldehyde 4-hydroxynonenal (HNE) is a LPO product that was found, at pathological 
concentrations, strongly related to the release of different catabolic and inflammatory 
mediators in OA. Transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2) acts as 
a key modulator for the expression of multiple cellular stress-response genes such as 
glutathione S-transferase A4-4 (GSTA4-4), an important HNE detoxifying enzyme. 
Protandim®, a commercial product composed of a mixture of natural antioxidant products 
is reported to activate and increase the levels of Nrf2 in different tissues. Objective: In this 
study we are evaluating the biological effects of Nrf2 activators such as, Protandim®, A-I, and 
6-Gingerol. Results: The activation of Nrf2 can lead to indirect blockage of inflammatory and 
catabolic responses as well as oxidative stress. Using human OA chondrocytes, we 
demonstrated that Nrf2 activation by Protandim®, A-I, and 6-Gingerol abolished interleukin-
1beta (IL-1)-induced metalloproteinase-13 (MMP-13), prostaglandin E2 (PGE2), and nitric 
oxide (NO). Furthermore, we showed that Nrf2 activation protects cells against H2O2-induced 
cell death. Interestingly, the oral administration of Protandim® reduces HNE production via 
GSTA4-4 activation. We found that Nrf2 protein and mRNA levels decrease in OA cartilage 
from human and mice and match GSTA4-4 changes. Moreover, the overexpression of this 
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nuclear factor abrogates IL-1-induced GSTA4-4 inhibition as well as HNE and MMP-13 
production. In our experimental mouse model of OA induced by surgical destabilization of the 
medial meniscus (DMM), we found that oral administration of Protandim® at 10 mg/kg/day 
reduces cartilage damage. Conclusion: This is the first in vitro and in vivo study to 
demonstrate the pathophysiological role of HNE in OA. In addition, this study indicates that 
Nrf2 activators abolish HNE production and number of factors known to be involved in OA 
pathogenesis. These findings render such activators clinically-valuable agents in the 
prevention of OA. 
 
Keywords: Osteoarthritis, cartilage, hydroxynonenal, glutathione S-transferase, Nrf2, 
catabolism, inflammation. 
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1. THE DIARTHRODAL JOINT 
The diarthroidal or synovial joint is the most abundant movable type of joint in the 
body of a mammal. Its encapsulated system consists of bone, articular cartilage, synovial 
membrane and synovial fluid [1]. Fig.1 shows a simplified synovial joint. 
 
1.1 Articular Cartilage 
Cartilage is a non-innervated anaerobic connective tissue found in many areas around 
the human body. There are three main types of cartilage classified according to the relative 
amounts of main components; elastic cartilage, hyaline cartilage and fibrocartilage. Cartilage 
constitutes mainly of sole type of cells named chondrocytes distributed within a mesh of an 
extracellular matrix (ECM). It can be divided into four zones according to the morphological 
changes in chondrocytes and matrix from the articular surface to the subchondral bone [1]. 
Fig.2 illustrates the structure and different zones within hyaline cartilage. A synovial joint 
contains hyaline cartilage which forms a protective layer covering the two bone ends of the 
joint to reduce contact stresses there and facilitate bone movement without pain. Moreover, 
articular cartilage protects bone surface from impact stresses, and minimizes friction and wear 
in the joint [1, 2]. Therefore, loss or destruction of cartilage can be associated with extreme 
pain especially during movement, which is often the case in advanced OA patients.   
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Figure 1 :  The structure of a healthy typical Synovial joint. 
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Figure 2: Schematic diagram of the cellular organization in the zones of articular 
cartilage (A) and of the collagen fiber architecture (B) (from Buckwalter et.al [3]).  
The composition, structure and functions of chondrocytes vary depending on their zone or 
location within the cartilage [4, 5]. In the superficial zone chondrocytes are in contact with the 
synovial fluid, cells are closely spaced and aligned with the cartilage surface. This zone, 
serves mainly to support the tensile stresses generated when compressive loads are applied to 
the cartilage. The transitional intermediate zone holds lower density of randomly dispersed 
chondrocytes and high concentration of proteoglycan and collagen. In the deep radial zone 
chondrocytes forms rows of cells parallel to the collagen fibers. The calcified zone is the 
innermost zone that connects the cartilage to the subchondral bone. This zone consists of 
lower count of chondrocytes uniquely capable of synthesizing type V collagen (Col V) which 
was presented as an important factor in the structural integrity to the less elastic subchondral 
bone [6]. 
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1.1.1 Chondrocytes 
Chondrocytes, the sole cellular component, form only 1-5% of cartilage volume, yet 
the highly specialized cells are responsible for producing other macromolecular components 
of the ECM. Depending on their location within the matrix the highly metabolically active 
chondrocytes can produce multiple collagen types including type II Collagen (Col II), Col VI, 
Col IX, Col X, Col XI, and proteoglycan among other mediators [2]. Chondrocytes are 
responsible for maintaining ECM integrity by controlling both the degradation and synthesis 
of matrix macromolecules. Though the exact process in still under study, it is believed to be 
under careful balance between multiple catabolic and anabolic mediators produced by the 
cells. Interleukin-1 beta (IL-1β) presents an example as it triggers a cascade of signals that can 
induce the expression of catabolic enzyme matrix metalloprotease-13 (MMP-13), up-regulate 
the expression of pro-inflammatory enzymes like cyclooxygenase-2 (COX-2) and molecules 
like prostaglandin E2 (PGE2), and affect the transcription of genes needed for the synthesis of 
proteoglycans [7]. On the other hand, cytokines, such as insulin-dependent growth factor-I, 
oppose these catabolic activities by stimulating matrix synthesis and cell proliferation. 
Chondrocytes can also produce tissue inhibitors of metalloproteinases (TIMPs) that antagonize 
the catabolic effect of MMPs. Furthermore, the interaction between chondrocytes and matrix 
in an interdependent pattern is essential for tissue maintenance and has huge effect on the 
metabolic activity of chondrocytes. [2, 7].  
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1.1.2 Extracellular Matrix (ECM) 
Articular cartilage derives its form and mechanical properties from its matrix 
[2].Water, the main component contributing up to 80% of the matrix, collagen and 
proteoglycans interact to gives tensile strength to the cartilage. The matrix also functions as an 
environment to protect chondrocytes from mechanical stress, store cytokines and growth 
factors needed to maintain cell function and activity, act as a media for nutrient diffusion to 
chondrocytes and as signal transductor for the cells [8]. Col II is the principal component of 
ECM accounts for 90-95% of collagen. Deformations in the matrix due to the of loss of 
balance between catabolic and anabolic factors in the cartilage can further alter the response of 
chondrocytes, and lead to overall abnormal cartilage structure and function such as the case in 
advanced OA [2] . Fig.3 shows main differences between normal and OA joint. 
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Figure 3: Normal joint vs. OA joint shows changes such as loss of cartilage integrity and 
erosion, loss of joint space and the formation of osteophytes. 
 
1.2 Bone 
The calcified zone of the cartilage is bordered by the subchondral bone plate, a very 
thin cortical bone structure to which the articular cartilage is anchored. Arterial terminal 
branches in the subchondral bone plate it can supply approximately 50% of the glucose, 
oxygen, and water required by articular cartilage [9, 10]. Bone cells include osteoblasts and 
osteoclasts secret factors that can affect the activity and differentiation of chondrocytes 
through crosstalk between subchondral bone and cartilage. Though the relationship is still 
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under investigation it is well reported that, changes affecting metabolic activity of bone cells, 
especially in the subchondral bone, may alter local signaling factors and trigger changes 
affecting near chondrocytes and articular cartilage in general [11]. 
 
1.3 Synovial Membrane 
The Synovial membrane is bi-layer membrane of connective tissue that lines the 
cavities of joints. There are two types of cells forming the innermost or internal layer of the 
membrane; fibroblast-like synoviocytes (FLS) and macrophages. While FLS are responsible 
for producing hyaluronan long chain sugar polymers [12], macrophages act to clear unwanted 
substances and debris [13]. This membrane seals off the synovial fluid from the surrounding 
tissue and plays essential role in supporting joint lubrication by secreting synovial fluid and 
other important macromolecules like hyaluronan. Moreover, the membrane acts to regulate the 
amount and content in it by controlling the passage or filtration of nutrients into the synovial 
capsule and the clearance of waste products from it [1, 11] . 
 
1.4 Synovial Fluid 
The synovial fluid is a viscose plasma dialysate secreted by the joint tissues especially 
synovial membrane characterized by high content of hyaluronic acid. The synovial fluid holds 
three main advantages; the viscous fluid lubricates the articulating surfaces, provides a media 
for carrying nutrients to chondrocytes, and clearing waste products from the cartilage while 
acting as a shock absorber [1]. Whereas cell counts of synovial fluid are normally low, healthy 
samples contain a detectable level of mononuclear cells. It has been suggested that the main 
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function of the mononuclear cells of synovial fluid is the removal of debris that normally 
appear in joints. However, the fact that vascular and synovial membrane permeability are 
altered by inflammation, accounts for changes in protein and cellular content in diseased 
synovial fluid [14]. Moreover, a direct correlation between high levels of leukocytes and 
synovial fluid pH was described in samples from patients with various forms of acute and 
chronic arthritis [15]. In addition, the level of different enzymes present in the synovial fluid 
can vary in the presence of articular disease. These enzymes could be either produced locally 
by the synovial membrane or released by synovial fluid macrophages or entering from plasma. 
Such changes can have strong implication on disease progression and symptoms development 
[1, 16]. 
 
2. OSTEOARTHRITIS (OA) 
 
2.1 Definition and classification  
OA is one of the most prominent chronic degenerative disease of the joints; it is the 
most common joint disorder in the world and the second most common diagnosis among 
ageing population [17]. Disease diagnosis and stage determination can be achieved through 
analyzing clinical and idiographic outcomes. Clinical examination evaluates symptom such as 
pain, local inflammation and change or limitation in joint function, while radiographic 
imaging can aid in viewing articular changes like deformations and joint space narrowing. The 
most commonly affected joints are the distal interphalangeal joints of the hands and weight 
baring joints such as the hips and the knees [18]. 
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OA is a multifactorial disease that is mainly characterised pathologically by 
progressive loss of articular cartilage in synovial joints. Moreover, disease development and 
progression also involves synovial inflammation, bone remodeling and increased 
inflammatory and catabolic responses. Therefore, OA is being considered a disease that affects 
the joint as an organ including cartilage, bone, synovium, muscles and ligaments [19]. The 
structural integrity of the matrix of human articular cartilage is maintained by a dynamic 
equilibrium between synthesis and degradation. In OA disruption of the differentiation and 
function of chondrocytes influences the composition and structure of the cartilage matrix. This 
disruption causes catabolic factors to overcome the anabolic capacity of chondrocytes leading 
to overall loss of normal ECM composition and cartilage properties.  
 
2.2 Epidemiology of OA 
Advanced OA is considered a major socio-economical problem not only in Canada but 
in the Western countries and the world. The disease significantly reduces the productivity, 
activity and quality of life of patients as well as exerting high stress on the health system. 
Moreover, an anticipated increase in OA prevalence within the next two decades is expected 
to make it the fourth leading cause of discordance, this increase is mainly attributed to ageing 
population, sedentary lifestyle and obesity epidemic [20].  According to a report published by 
the Arthritis Alliance of Canada in 2011 titled “The impact of arthritis in Canada: today and 
the next 30 years”, the prevalence of OA is expected to further increase in Canada to reach 
71% by 2040 among seniors above the age of 70 years old.  
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OA can be generally classified into two forms either as primary or secondary OA. 
While the primary form of the disease is the most common type, it is considered as an 
idiopathic phenomenon that is usually related to aging process, typically occurring in older 
individuals. Though primary OA has no specific apparent trigger or initiating factor, multiple 
risk factors can play a role in disease progression. However, secondary OA refers to damage 
affecting the synovial joint as a result of predisposing condition like trauma or congenital 
deformity and can happen earlier in life [21]. Risk factors; OA can be considered as the 
product of an interaction between different factors; these factors can be categorized as 
systemic risk factors affecting the biological activity of the body or local risk factors that exert 
an influence on specific joint or joints. Systemic risk factors; age is considered as the strongest 
factor for OA development and progression where changes in biological functions are 
associated with cumulative exposure to different risk factors [21]. Women have higher 
prevalence not only for developing OA but for having more severe form of the disease 
especially during and after menopause [22, 23]. Therefore, both gender and hormonal factors 
are considered to be important risk factors. Race and ethnicity can also play a role where 
studies on different location revealed variation in OA prevalence and joints affected. For 
example, African Americans reported more joint and hip symptoms than whites in general 
[24]. Further study is needed to comprehend the origin of this variation. Moreover, factors 
such as genetics and the presence of congenital or developmental conditions also have an 
influence on disease progression [25]. Local risk factors; obesity is highly targeted as a potent 
risk factor for developing OA particularly in weight-bearing joints especially the knee. 
However, weight loss and exercise were found to reduce pain and risk of developing 
symptomatic OA. Knee surgery or injury are considered among the strongest risk factors 
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especially for early OA of the knee, also having an occupation or playing certain sports that 
exerts strong impact or strain on certain joints can increase the prevalence for developing OA 
[21, 26]. 
 
3. PATHOPHYSIOLOGY OF OA 
 
OA is described as a disease affecting the whole joint. However, articular cartilage is 
considered a major target of tissue injury that is most related to symptoms development and a 
hallmark of disease progression regardless of triggering factors. Alterations in ECM and 
cartilage are associated with changes in chondrocyte and disruption of homeostasis leading to 
loss of the balance between anabolic and catabolic pathways necessary for maintaining the 
properties of cartilage tissue. Studies on OA indicate that cytokines and growth factors are 
implicated in the disease. Degradation of cartilage ECM and the suppression of its 
biosynthesis by chondrocyte are regulated by the release of several cytokines in the joint.  
According to the triggered response these factors can be classified as proinflammatory, which 
are generally also catabolic (e.g. IL-1, IL-6, IL-8, and tumor necrosis factor-alpha (TNF)), or 
anti-inflammatory (e.g. IL-4, IL-10, IL-13). Other factors like IL-1 receptor antagonist (IL-
1Ra) and interferon-gamma (IFN-ɣ) are also classified as inhibitory cytokines, since they may 
block the actions of catabolic cytokines. Though many of these factors are necessary at low 
levels for normal homeostasis, in OA disruption in their level can indicate an important role in 
the disease. Despite the absence of clear or specific initiating factor, the progression of the 
disease is mostly regulated by pro-inflammatory cytokines mainly IL-1β and TNFα [27, 28] 
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3.1 Pro-inflammatory mediators  
In OA, upregulation of cytokines production such as IL-1β and TNFα in synovial 
membrane leads to increase in their level in cartilage triggering the activation of chondrocytes. 
Upon activation by IL-1β, cells show a pronounced upregulation in gene expression of MMPs, 
inducible nitric oxide synthase (iNOS) and COX-2, as well as in the synthesis of inflammatory 
mediators such as PGE2 and nitric oxide (NO). Current research on OA suggests a central role 
of IL-1β in joint destruction and other pathological features of the disease.  While IL-1β is 
largely involved in the induction of catabolic effect on cartilage in OA, TNFα is presented 
more as an inducer of the inflammatory effect [29].  Further investigating its effect indicated 
cytokine ability to induce deleterious changes in chondrocyte function and in the integrity of 
ECM. In addition, understanding cytokine-induced signal transduction pathways involved the 
OA and/or normal cartilage homeostasis can provide new potential targets for intervention in 
OA  [30, 31].  In fact, several clinical trials have tried to modulate the effect of major 
cytokines in order to control their role in OA pathogenesis. This approach had several 
successes in rheumatoid arthritis (RA). For example, the administration of TNF antagonists 
have been effective in treating RA, yet TNF antagonist therapy has less dramatic effects in 
patients with OA. Clinical trials on the use of several inhibitors of biological targets propose 
certain factors as part of the disappointing outcome such as side effects of medication, time of 
intervention and pharmacokinetics of the used agents  [32].  
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3.1.1 Pro-inflammatory cytokine IL-1β 
IL-1β protein is primarily produced as a precursor (pro-IL-1β) that needs to be 
processed by caspase-1 to generate its mature and active cytokine. Upon binding its type 1 
receptor (IL-1RI), IL-1β triggers several pathways leading to activation of several signal 
transduction kinases as well as inducing nuclear translocation of number of transcription 
factors. These effects can be inhibited by naturally present IL-1Ra and type2 IL-1 decoy 
receptor. Several studies have presented strong indications of the significant role played by IL- 
1ß in OA [30]. In normal articular tissue the cytokine is produced in limited amount. However, 
its level markedly increased in chondrocytes as well as synovial cells from patients with OA 
[33]. The reported increase in IL-1β production and also in cellular response to the cytokine 
might be explained by several observations; while the level of IL-1 antagonists in OA 
synovium is downregulated, there is a concomitant upregulation of IL-1β-converting enzyme 
and IL-1RI in human chondrocytes and synovial fibroblasts. Therefore, these observations 
may provide a molecular explanation for the enhanced catabolic effects of IL-1β in OA joint 
tissues.  
The destructive effects of IL-1β in OA include both elevation of cartilage catabolism 
and suppression of cartilage anabolism. IL-1β can trigger multiple signal transduction 
pathways that upregulates gene expression and subsequently the levels of major extracellular 
proteolytic enzymes involved in cartilage degradation such as MMPs [34]. In addition, the 
cytokine has the capacity to induce several proinflammatory mediators involved in the 
increase of local hematopoietic cells during OA. An increase in articular hematopoietic cells 
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can cause increases in oxidative burst activity and decreases in O2 concentration, and 
generation of additional inflammatory and proteolytic enzymes that can lead to progression of 
OA [30]. Among proinflammatory mediators induced by IL-1β the upregulation in gene 
transcription of iNOS and COX-2 that causes a subsequent increase in levels of NO and PGE2 
respectively hold significant importance in the pathology of OA. The detrimental effects on 
articular tissue associated with significantly high levels of these proinflammatory mediators 
have been closely investigated in the literature [30, 31]. Moreover, the cytokine can also 
induce downregulation in biosynthesis of Col II, major articular joint protein as well as 
through stimulating chondrocyte apoptosis [35]. As a result, IL-1β can decrease ECM 
synthesis by affecting the anabolic activities of chondrocytes and/or the cell densities of 
articular cartilage. Consequently, the outcomes of triggering of IL-1β pathway in OA can be 
related to deleterious effects that include both elevation of cartilage catabolism and 
suppression of cartilage anabolism [30]. 
Several strategies aiming to inhibit or modify the activity of IL-1 have been 
investigated as possible treatments in OA such as the administration of IL-1Ra and soluble IL-
1 receptors. The results of these investigations revealed potential agents that may be used in 
the treatment of OA. However, further research is needed to establish sufficient data about its 
safety and effectiveness. The role of different IL-1 inhibitors in OA has been discussed in an 
evidence based review [36]. 
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3.1.2 COX-2 and PGE2 
Cyclooxygenase (COX) also named prostaglandin H synthase is the main enzyme in 
the metabolism arachidonic acid (AA) and subsequent production of prostaglandins (PG).  
Membrane-bound phospholipids are converted into AA through phospholipase A2 activity. 
COX enzymes convert AA first to PGG2 and then to an unstable metabolite PGH2 that will be 
rapidly converted into three types of prostanoids: prostaglandins, thromboxanes, prostacyclins 
in addition to leukotrienes [37]. Currently, three isoform of COX enzyme have been identified 
each encoded by a different gene. The inducible nature of the isoforme COX-2 expression by 
several mediators such as pro-inflammatory mediators like IL-1β and TNFα and lipid 
peroxidation (LPO) product 4-hydroxynonenal (HNE) made it a target for closer investigation 
[38, 39]. COX-2, but not other isoforms, synthesis was significantly increased in different 
diseases known to be of inflammatory nature is well reported in disease-related pattern. The 
increase in both mRNA and protein levels of COX-2 in arthritic joint tissues of animal models 
of joint inflammation indicate an important role played by the enzyme in arthritic articular 
tissues [40]. PGE2, the most abundant PG produced in the articular tissue, is involved in many 
physiological events, such as cell growth, immune regulation, and inflammation. Three 
prostaglandin-E synthase (PGES) isozymes, each encoded by a separate gene, are responsible 
for PGH2 isomerization to produce PGE2. Further studying the activity of microsomal-PGES 
(mPGES) isoforme showed inducible nature in the presence of inflammatory stimuli providing 
an interesting target in the development of inflammatory arthropathies. Both COX-2 and 
mPGES are key enzymes for PGE2 biosynthesis especially under inflammatory conditions 
[39].  
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The study of OA cartilage specimens indicated not only the expression of COX-2 but 
also showed spontaneous increase in PGE2 levels that are at least 50-fold higher than normal 
cartilage [41]. Therefore, the noticed increase in local PGE2 production, suggests an 
attribution through COX-2 activity. However, recent evidence was provided that PGE2 in 
human synovial fibroblasts can also play a role in controlling COX-2 expression through a 
positive feedback mechanism [42]. In OA, PGE2 is well reported to induce a catabolic effect 
where it can inhibit collagen expression, increase the production of MMPs, and modulate bone 
resorption by stimulating osteoclasts activity [43, 44]. PGE2 has also apoptotic effect on 
chondrocytes by enhancing NO-induced apoptosis. In addition, other researchers suggested a 
direct apoptotic role for PGE2 perhaps through cAMP activity [45].  
The expression of COX genes is highly regulated. The inducible nature of COX-2 gene 
expression is regulated through its gene promoter which contains several inducible enhancer 
elements [46]. Several stimulators can interact with these elements to play a role in COX-2 
gene expression through different pathways. Interestingly, 15d-PGJ2, the endpoint metabolite 
of PGD2 is found to prevent IL-1β induced COX-2 expression and PGE2 production [47]. Yet, 
it also induced COX-2 expression but not PGE2 production in the absence of IL-1β. This 
observation suggests the presence of another signaling pathway involved in PGE2 production 
with IL-1β stimulation on which 15d-PGJ2 inhibitory effect takes place [39].  
The use of COX-2 specific inhibitor caused marked suppression in COX-2 expression, 
PGE2 production, along with swelling, and cellular infiltration in the joints [48]. It was also 
shown that pre-treating rat models with neutralizing anti-PGE2 monoclonal antibodies 
prevented signs of tissue inflammation, presenting PGE2 as a valuable target for preventing 
symptoms of inflammation [49]. Non-steroidal anti-inflammatory drugs (NSAIDs) are among 
 18 
the most widely prescribed drugs. They work by inhibiting COX enzymes in a non-specific 
way. Majority of the reported undesirable effects of NSAIDS are attributed to COX-1 isoform 
inhibition. Therefore, developing agents to specifically block COX-2 while 
simultaneously keeping COX-1 activity unaffected is considered a rational approach to obtain 
efficacy without deleterious side effects. COX-2 specific agents, generally called coxibs, are 
the most common clinically prescribed drugs as analgesics and for the management of several 
conditions including OA. Coxibs proved to be effective with significant reduction in known 
side effects usually associated with conventional NSAIDs usage [50]. However, recently 
concerns are rising regarding the permanence of some gastrointestinal and renal side effects, 
also regarding potential cardiovascular adverse effects. Up to date results released are 
considered inconclusive triggering the need for developing new agents or targets that help 
better control the expression and activity of COX-2 and PGE2 [51]. 
Amongst COX-2 and mPGES-1 gene expression inducers HNE is also reported to act 
as inflammatory mediator that enhances protein and mRNA levels by affecting gene promoter 
activity in dose-time dependant pattern [45, 52]. This induction is also associated with 
increases in PGE2 production. The expression of COX genes is highly regulated. The 
inducible nature of COX-2 gene expression is regulated through its gene promoter which 
contains several inducible enhancer elements. Several stimulators can interact with these 
elements to play a role in COX-2 gene expression through different pathways. For example, 
the cytokine IL-1β induces gene expression via mitogen-activated protein kinase (MAPK) and 
protein kinase C (PKC) pathways while HNE appears to modulate different pathways that 
affect COX-2 and mPGES-1 expression such as p38MAPK signaling pathway [45, 52]. 
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Interestingly, 15d-PGJ2, a potent activator of peroxisome proliferator-activated 
receptor gamma (PPARɣ), is found to prevent IL-1β induced COX-2 expression and PGE2 
production. Yet, this endpoint metabolite of PGD2 could induce COX-2 expression but not 
PGE2 production in the absence of IL-1β suggesting the presence of another signaling pathway 
involved in PGE2 production with IL-1β stimulation on which 15d-PGJ2 inhibitory effect 
takes place [39, 47].  
 
3.2 Catabolic molecules  
The maintenance of healthy cartilage requires a system of ongoing balance between 
building and breaking mechanisms. However, when a shift in the endogenous system causes 
increases in the catabolic activity it leads to increase in cartilage ECM degradation. In OA, the 
destruction of cartilage components is considered a central character of disease development 
especially the degradation of Col II by collagenases activity of MMPs such as MMP-13 [53]. 
Moreover, other molecules can also contribute to the catabolic process like the free radical NO 
which is considered among the main molecules that mediate catabolic changes [54] .  
 
3.2.1. MMPs 
 MMPs are a group of endopeptidase that share similar structure. Since their 
discovery the enzymes were studied for their function within different tissue not only for 
connective tissue remodeling, but also in wound healing, angiogenesis, and metastasis as well 
[55]. Among the group four enzymes MMP-1, -8, -13 and -14 have collagenolytic activity 
and are capable of breaking the highly stable fibrillar collagen. Samples from synovium and 
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cartilage from OA and RA patients showed an increase in the activities of several MMPs. 
However, an upregulation in cartilage expression and activity of collagenase-3 (MMP-13) in 
OA cartilage present the enzyme as the primary collagenase in OA [53, 56]. In arthritis 
endogenous inhibitors of MMPs such as TIMPS are produced; however their activities are not 
sufficient to compensate for the increase in catabolic activity of MMPs [57]. 
In an effort to reduce/manage the catabolic activity of MMPs, a number of MMP 
inhibitors have been developed and tested in various animal models of arthritis. An inhibitor 
of the collagenases (MMP-1, -8, and -13) prevents cartilage degradation in animal models of 
both RA and OA [58]. Other MMP inhibitors were tested in arthritis clinical trials, but serious 
side effects mainly due to lack of specificity have largely hindered their further development 
[59]. MMP-13 is known to be activated by a number of mediators, such IL-1β. In OA, the 
increase in MMP-13 expression and activity might therefore be attributed, in part, to the 
increase in IL-1β release in the synovial fluid [60, 61]. 
Moreover, locally produced inorganic oxidants were found capable of degrading 
cartilage mainly by inducing the oxidation of ECM components and/or posttranslational 
modification of MMPs [62, 63]. Moreover, reactive oxygen species (ROS) might shift the 
balance of proteolytic potential by decreasing the production and/or the activity of TIMPs 
[64]. In addition, HNE can also induce MMP-13 expression at protein and mRNA levels. [65-
68]. Interestingly, an earlier study revealed that the pathway needed for activating the 
transcription and protein synthesis of MMP-13 by HNE is different from the pathways 
triggered by proinflammatory mediators like IL-1β and TNF-α. Whereas IL-1 induction of 
MMP-13 gene expression requires the activity of p38 and, c-Jun N-terminal kinase (JNK) 
with the translocation of NF-κB translocation [66], TNF-α triggered MMP-13 gene 
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expression involves MAPK, activator protein 1 (AP-1) and NF-κB [65]. Nevertheless, HNE 
induction of MMP-13 transcription requires p38 MAPK activity with possible role of AP-1 
and c-Jun but not NF-κB [67]. 
 
3.2.2 Inducible nitric oxide synthase (iNOS) and NO in OA 
NOS is the enzyme responsible for the production the highly reactive molecule NO 
through l-arginine metabolism. The enzyme is present within different tissues in three 
isoforms; neuronal (nNOS) and endothelial (eNOS) and inducible (iNOS). The constitutive 
nNOS and eNOS produced low level of NO play an important role in intercellular signaling 
and the homeostasis in neurons and endothelial cells [69, 70] . However, in the presence of 
certain stimuli like inflammation the release of certain cytokines and mediators such as IL-1β 
and TNFα can trigger the transcription and activity of iNOS; as a result large quantities of 
NO are produced [71]. In fact, the inducible production of NO is significant not only for 
inflammatory, and immunological host defense responses, where NO can exert cytotoxic 
effects against microbes, but for tumor cells and tissue repair as well [72] 
Earlier studies indicated the presence of higher levels of NO in human synovial 
fluids from RA and OA patients when compared with normal samples [73]. The observation 
suggests an important role for the free radical as a mediator of inflammation in both diseases. 
In OA, sustained high levels of inflammatory cytokines especially IL-1β leads to prolonged 
activation of iNOS usually in the presence of highly oxidative environment. The release of 
high amount of NO in the presence of superoxide anion leads to the formation of the highly 
reactive peroxynitrite which in turn induces proapototic and proinflammatory responses in 
cells [74-77].  In chondrocytes, NO is not only cytotoxic; in fact, the molecule has an 
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additional predominant catabolic effect where it inhibits the synthesis of ECM components; 
Col II [78] and proteoglycan [79], as well as activating MMPs [80]. These observations 
indicate essential role of induced NO release and its derivatives as mediators in OA 
pathogenesis through different mechanisms [81]. 
The production of NO by chondrocytes and synoviocytes in OA is regulated by the 
level of NOS transcription and translation. Therefore, several studies tested the effect of 
different inhibitors of NOS in OA and RA. Such studies helped also elucidate the role of iNOS 
and NO as mediators in disease pathogenesis. Studies on animal models of OA using different 
inhibitors such as NG-monomethyl-t-arginine (NMMA) and specific iNOS inhibitor N-
iminoethyl-L-lysine (L-NIL) showed interesting and promising findings in RA and OA 
respectively. The data showed that the inhibition of iNOS results in marked suppression in 
tissue destruction associated with chronic inflammation [82, 83]. In a study on an animal 
model of RA, the administration of NMMA greatly reduced leukocytes effusion, joint erosion 
and other signs of inflammation in the area. Interestingly, the beneficial effect was not limited 
to earlier stages of the arthritis, but it was also present at the chronic phase of the disease [84].  
Similar results were also obtained by selectively inhibiting iNOS in experimental OA model 
using L-NIL. The inhibition of iNOS was associated with reduced production of NO in tissue 
which also resulted in a significant decrease in the production of catabolic factors such as 
MMPs and peroxynitrite [83]. In a more recent study in OA the use of L-NIL could also 
prevent NO-induced lipid peroxidation and subsequent production of highly reactive toxic 
compounds like HNE; a key mediator in OA [85]. Moreover, L-NIL significantly reduced the 
cytotoxic, proinflammatory and catabolic effects induced at different pathological 
concentrations of HNE. L-NIL also blocked the inhibitory effect of IL-1β on glutathione S-
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transferase (GST) and the stimulation of ROS in a dose dependent pattern [85]. The reported 
beneficial effects of NOS inhibitors indicated a potential promising protective effect on 
chondrocytes in OA. 
 
            4. THE OXIDATIVE STRESS IN OA 
  
Closer study of the chronic degenerative nature of OA led to significant shift in the 
search for therapeutic solutions for the disease. In fact, most available pharmacological agents 
targeting the formation of inflammatory mediators have not provided a real solution for OA. 
Therefore, there is an essential need for other secondary therapies designed to prevent the 
progression of this chronic disease. Current attempts based on recent data aim to develop 
effective chondroprotective disease-modifying agents to control different molecular pathways 
involved in the initiation and progression of OA. Oxidative stress within articular tissue has 
been pointed out as an aspect with a significant role in the pathogenesis of OA, an observation 
supporting the predicted therapeutic potential of targeting pathways involved in joint 
metabolism controlled or affected by oxidative stress [86, 87].  
Though physical exercise is important for maintaining normal cartilage function, 
excessive repetitive mechanical load and sheer stress can trigger apoptotic and inflammatory 
responses in chondrocytes. The increase in ROS production within the articular tissue due to 
excessive mechanical load and stimulated pro-inflammatory mediators can lead to diffusion of 
free radicals into cartilage. Interestingly, studies also show a concomitant decrease in the 
protective antioxidant response within the joint leaving chondrocytes highly prone to cell 
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death through caspase activation mediated by the oxidative radicals [88].  Moreover, research 
on the effects of ageing show that cartilage homeostasis is highly affected by ageing process 
where chondrocytes are less responsive to mechanical anabolic stimuli.  This observation can 
be correlated with our knowledge about OA to explain much higher incidence of the disease 
among older patients. Another condition affecting cartilage termed cellular senescence may 
lead to an irreversible arrest of chondrocytes growth causing detrimental outcomes on 
cartilage homeostasis relevant to cartilage ageing. A study by Yudoh et al. [89] investigated 
the role of oxidative stress and reactive radicals in cartilage senescence and in the 
development of OA. The study demonstrates that high level of oxidative stress affects 
chondrocytes in the presence of profound decrease in antioxidative capacity of articular tissue. 
Consequently, the oxidative stress induces a mechanism triggering the acceleration of 
chondrocyte senescence by causing abnormal erosion of cellular telomere end. Therefore, 
oxidative stress is considered closely involved in cartilage senescence and the development of 
OA. In addition, both mechanical and chemical stressors may alter cellular adaptation to 
hypoxia during disease progression, causing oxidative damage and changes in the 
microenvironment ultimately negatively affecting the synthesis of chondrocytes [89]. The 
same study reported an important reduction in the antioxidative potential in degenerating 
regions in comparison with the intact regions from the same OA articular cartilage sample. 
Obtained results suggested that oxidative damage can induce catabolic changes to cartilage 
matrix in articular cartilage. Furthermore, the treatment of cultured cartilage with an 
antioxidative agent showed a protective effect against the observed oxidative stress-induced 
chondrocyte dysfunction and cartilage damage. Collectively these findings support the theory 
focusing on oxidative stress as an inducer of catabolic changes in cartilage matrix [89]. 
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4.1. Oxidative stress and antioxidant molecules 
Reactive molecules are normally present within a biological system. Different 
reactive species can be produced as byproducts of normal activities such as aerobic 
metabolism, during pathological conditions or result from external resources such as pollutants 
and cigarette smoke. At certain concentration reactive radicals do play a role in regulatory 
functions, cell signaling and in immunological response [90]. However, when present in large 
volumes, reactive molecules can interact with and damage major cellular components like 
proteins, lipids and DNA [90]. The induced damage can be attributed to the production of 
peroxides and free radicals like ROS and reactive nitrogen species (RNS). To avoid excessive 
cellular damage the body contains number of defense and protective mechanisms including 
continuous repair machinery and the antioxidant system. Disturbances in the balance between 
produced oxidative molecules and available reducing agents due to uncontrolled production of 
free radicals with or without a decline in reduction capacity of the cells can cause tissue 
damage in several pathophysiological conditions [91]. Under such conditions the cell is 
considered under oxidative stress. The effect of this stress on the cell and the body overall 
depends on the extent of damage caused by the reactive species and on cell’s ability to 
constantly repair any damage. At different levels oxidative stress can cause several changes in 
cellular response. The induced effect may range from inducing altered cellular activity by 
affecting cell signaling pathways; either directly as chemical messengers or indirectly via 
modifying cellular components involved in the pathway such as lipids, to induce apoptosis. 
Moreover, under severe levels of oxidative stress the accumulating damage can prevent the 
cell from undergoing programmed cell death and cause necrosis [92, 93]. 
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The antioxidant system contains different enzymes which protect against oxidative 
stress. Moreover, the role of antioxidants in controlling the production of inflammatory 
cytokines, LPO and the activation of transcription factors which trigger other inflammatory 
components is of major importance in several pathological conditions. The enzymes 
glutathione peroxidase (GPx), heme oxygenase-1 (HO-1) and superoxide dismutase (SOD) are 
among the best studied cellular antioxidants. In OA, studies indicated the importance of GSX, 
HO-1, SOD2 and SOD3 in the oxidative defense in cartilage [86, 94]. In addition, there is a 
well reported change in the expression of these genes in OA chondrocytes and in the presence 
of inflammatory cytokines such as IL-1β [86, 90].  
Antioxidant molecules such as ascorbic acid, flavonoids, N-acetyl-cysteine (NAC) 
and glutathione (GSH) have been shown to play an important role in different inflammatory 
diseases such as atherosclerosis, arthritis and OA [95, 96]. In particular GSH, the substrate for 
GST and GPx, have shown a promising protective role in OA [97].  
 
 4.2. Reactive oxygen species (ROS) 
Aerobic cellular activities such as cellular respiration can produce oxygen 
containing reactive molecules named ROS. The highly reactive molecules and the less reactive 
of these species are important for redox signaling pathways [98]. The immune system also 
benefits from the destructive activity of ROS in killing pathogens [99]. However, due to their 
high reactivity, ROS are widely linked to the induction or aggravation of different pathological 
conditions such as atherosclerosis, cancer, neurodegenerative disease and OA [90]. The 
production of ROS is not solely influenced by internal mechanisms but external sources like 
environmental toxins can also induce their generation within the body. Therefore, the role of 
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antioxidants within the biological system is considered primordial to maintain an optimal level 
of these molecules at all times [100].  
In OA, several ROS have been closely studied as main factors in the pathology of 
the disease. While articular cartilage is an avascular tissue that depends on nutrient supply 
needed for basic cellular functions from the synovial fluid, chondrocytes are adapted to work 
within low oxygen pressure to anaerobic environment [101]. In pathological conditions 
associated with OA, fluctuations in partial oxygen pressure, mechanical stress and 
inflammatory mediators such as IL-1β can put chondrocytes under the influence of oxidative 
stress. Subsequently, significant increase in the production of ROS such as NO and O2- takes 
place. Different ROS molecules can further interact to generate reactive radicals, including 
peroxynitrite (ONOO−) and hydrogen peroxide (H2O2). Moreover, recent studies reported 
increase in the production of myeloperoxidase (MPO) in OA as well [102]. In the presence of 
H2O2 and Fe
+2, chondrocytes produce hydroxyl radicals (OH.). The highly reactive radical can 
initiate further series of reactions with unsaturated fatty acids within the lipids of cell’s 
membrane. Chain reactions can then result in the formation of other lipid radicals with much 
longer half life (RO.,ROO.) such as LPO end product HNE [103]. The role of oxidative stress 
along with produced ROS and LPO end products in OA is a subject for deep investigation and 
research. 
 
4.3 Lipids within the cell 
 Lipids are one of the major building blocks of the eukaryotic cell. Different forms 
of lipids such as; fats and fatty acids, phospholipids, certain vitamins, and steroidal 
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hormones are essential for the structure and function of living cells. Earlier opinions focused 
on lipids as a source of storage and provision of energy through their oxidation however, a 
much complicated and diverse role in the regulation of biological processes have been 
described later on [104]. For example, lipids can act as chemical messengers in cellular 
signaling; they are involved in hormone regulation, membrane lipid layer formation, and 
cholesterol synthesis (cholesterol is also the precursor of bile acids, vitamin D and steroidal 
hormones). The hydrophobic properties of lipids make them excellent candidates for signaling 
as they can diffuse through  different membranes to carry signals by binding to either 
membrane-bound or intracellular receptors [105]. Lipids can act as potent chemical 
messengers for paracrine, autocrine, and endocrine signaling forming a complex signaling 
network. In fact, imbalances in this network can be associated with different pathological 
conditions [106].  Interestingly,  the essential fatty acid linoleic acid has an important role as 
precursor for the formation of prostaglandins which was first described by Samuelsson et al in 
1964 [107, 108]. Prostaglandins in turn play a significant role in inflammation and other 
diseases including OA [39, 107].  
 
4.4. Lipid peroxidation (LPO) 
The lipids within the cell can undergo non-enzymatic oxidative degradation by 
ROS, especially when the cell is under oxidative stress.  Polyunsaturated fatty acids (PUFAs) 
within the cellular membrane are main target for different ROS due to the presence of multiple 
double bonds within their structures. The breakdown of PUFAs within cellular membrane can 
lead to further oxidative reactions and the production of potentially toxic LPO-end products. 
In the absence of protective antioxidant response, the self-propagating nature of the chain 
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reaction can result in significant tissue damage starting from the oxidation of only a few lipid 
molecules [109].  
The production of advanced LPO-end products (ALEs), such as aldehydes, within 
the cell is of special interest because of their unique biological properties and potential role in 
different pathological conditions. ALEs are more stable and have longer half life than ROS, 
making their ability to form protein adducts causing protein dysfunction and affecting cellular 
response of major importance. Moreover, the rates of ALEs production and protein adduct 
formation increase along with reduction in antioxidant capacity, such as during ageing, 
causing the accumulation of ALEs and modified proteins [110]. Depending on their target 
protein, different ALEs can be associated with different pathological conditions, such as 
atherosclerosis, asthma and OA [67, 111-113]. Whether studied LPO-products are the cause of 
a certain disease or they are merely produced as a result of the pathological condition, is still 
under investigation. However, the role of LPO-products in disease progression is predominant 
[109]. The process of LPO can affect the cell on different levels; disturb the structure of the 
cellular membrane, causing changes in its fluidity and permeability, and affect metabolic 
processes and ion transportation through the membrane [114].    
During LPO three main steps take place; initiation, propagation, and termination. 
The initiation phase generally results in the abstraction of a hydrogen atom. In the case of 
PUFA the initial reaction with radicals produces lipid radical (L•), which then reacts with 
oxygen molecules to form a lipid peroxyl radical (LOO•). In the next step, the LOO• can 
become lipid hydroperoxide (LOOH) by abstracting hydrogen atom from another fatty acid 
molecule which in turn becomes a second lipid radical [115]. In the presence of reduced 
metals, such as Fe+2, a reductive cleavage of LOOH can occur producing lipid alkoxyl radical 
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(LO•). Both alkoxyl and peroxyl radicals can abstract additional hydrogen atoms from other 
fatty acid molecules thereby triggering lipid peroxidation chain reaction [116]. Additionally, 
in the presence of reducing agents like ascorbate, LOOH can break to produce reactive 
aldehydes, such as malondialdehyde (MDA), HNE, and 4-hydroxy-2-hexenal (4-HHE) [117]. 
LPO products such as HNE can then interact with proteins, peptides, phospholipids, and 
nucleic acids within the cell. As a result, HNE can act as second toxic messenger affecting 
cellular pathways and causing cytotoxic, mutagenic and genotoxic changes [118, 119]. 
 
4.5. HNE 
4.5.1. Synthesis and characteristics of HNE  
The α,β-unsaturated hydroxyalkenal is the primary LPO product in cells from ω−6 
PUFA such as linoleic acid and arachidonic acid [118]. HNE is normally found within 
different biological tissues at basal concentration where it acts as second messenger [120]. 
However, the increase in its level especially during oxidative stress is being linked to different 
pathological conditions. The electrophilic nature of HNE due to its α,β-unsaturated carbonyl 
makes it highly reactive to cellular nucleophiles such as proteins especially via 1, 2- and 1, 4-
Michael addition. These properties make HNE at level beyond its basal concentration to 
possible toxicity to the cell [118, 121] 
 
4.5.2. Metabolism of HNE 
The role of HNE in the pathology of several diseases made intracellular HNE 
degrading pathways an important part of the antioxidative defense system. By preventing the 
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accumulation of aldehydic LPO-products, these pathways can protect proteins from 
modification by the reactive compounds. HNE is metabolized mainly through intracellular 
metabolism by different mechanisms including Michael additions, oxidation and reduction 
[122]. Several enzymes such as alcohol dehydrogenases, aldehyde dehydrogenases, and GST 
in addition to cofactors like NAD+ and NADH are needed for these reactions to take place 
[123]. The cellular capacity for HNE enzymatic metabolism depends on the level and 
availability of the metabolizing enzyme and/or cofactor. For example, though GST is present 
in almost all cell types the availability of this pathway is controlled by the level of GSH within 
the cell. Therefore, when a rapid or prolonged increase in HNE production leads to a fast 
decrease in intracellular level of GSH, the role of this antioxidant in HNE detoxification is 
greatly compromised [121]. 
 
4.5.3. HNE trapping molecules (Carnosine, N-acetyl-cysteine, Glutathione) 
The high bioactivity of HNE can be attributed to mainly to the electrophilic nature 
of its α,β-unsaturation. This character makes cellular nucleophiles such as GSH amino acids 
cysteine, lysine and histidine within side chains of proteins main target for the aldehyde. The 
interaction between HNE and a nucleophile results in the formation of adducts especially 
Michael adducts formation, a stable and strong bond [121]. The same reaction is also a method 
for HNE detoxification where forming similar adducts with reducing molecules like GSH 
hinders free HNE molecules preventing their interaction with other cellular components. 
However, benefiting of this pathway as reliable detoxification method depends on the 
presence of elevated levels of the reducing agent GSH. Exogenous neucleophilic compounds 
such as Carnosine (CAR) and NAC can interact with and trap free HNE molecules by forming 
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stable covalent adducts. Therefore, such compounds referred to as HNE-trapping molecules 
are being studied for possible protective properties to prevent deleterious effect of free and 
protein-bound HNE molecules on cellular components [124]. Additionally, these compounds 
can be used to investigate the effect of free HNE molecules and HNE modified proteins on the 
cell. The natural antioxidant GSH (Glu–Cys–Gly) is essential for maintaining antioxidants in 
an active state, and exerts high detoxification reactivity against HNE. CAR, a natural 
antioxidant composed of β-alanyl-L-histidine dipeptide has been found to inhibit HNE-
induced protein modification in cartilage and other tissues by directly binding to free HNE 
molecule or displacing bound HNE off protein surface. Therefore, CAR is being presented as 
a quencher of highly cytotoxic aldehydes [125]. Another amino acid derivative NAC has 
highly protective scavenging properties against HNE and MDA. Studies reported that the 
pretreatment with NAC protects chondrocytes against HNE-induced apoptosis in chondrocytes 
and several cell lines [97]. 
 
4.5.4. HNE and GSTA4-4  
GSTs are important enzymes for cellular metabolism and detoxification. GST 
facilitates the conjugation between GSH molecule and an electrophilic center like HNE.  In 
fact GST is more than 600 times more active than the non-enzymatic Michael addition 
reaction. Under oxidative stress or in case of pathological condition, high LPO rates accelerate 
HNE formation. The increase in GST activity to neutralize the produced HNE can lead to a 
concomitant fast drop in intracellular GSH concentration [122]. GSTs could also aid in 
reducing hydroperoxide formation during LPO process leading to less HNE generation [126]. 
Among different isoforms, GSTA4-4 plays an important role in the detoxification of HNE 
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within articular tissue due to its high catalytic efficiency with the toxic aldehyde [127]. On one 
hand, studies on OA showed that the loss of GSTA4-4 enhanced the cytotoxic effect of HNE 
on chondrocytes. On the other hand, enzyme’s overexpression succeeded in protecting the 
cells from HNE-induced cell death [97].  
 
4.5.3. HNE in OA 
Research on OA showed increased production of LPO-products especially MDA 
and HNE in articular tissue. Moreover, synovial fluid samples from OA patients revealed 
significant increase in the levels of HNE adducts in OA samples in comparison with control 
subjects There is also evidence that the influence of HNE follows dose dependant pattern, 
where at lower concentration (≤10 µM) HNE acted as an important mediator of catabolic and 
inflammatory processes in OA. At higher concentration ≥20 µM, HNE had pronounced 
cytotoxic effect on chondrocytes [97, 125] . This important influence of HNE on the cell is 
caused mainly by its interaction with cellular proteins especially through the formation of 
adducts. HNE-modified proteins may show various changes in their function and/or activity 
[125, 128]. HNE is capable of affecting a wide array of biological activities, such as signal 
transduction, gene expression, and modulation of cell proliferation [129] mainly by 
modulating the expression of different genes [130]. Such HNE-induced effects including 
apoptosis are well reported in several cell types of different origins including chondrocytes 
[131]. However, HNE cytotoxicity was preventable in the presence of antioxidant agent NAC 
or by the overexpression of HNE-detoxifying enzyme GSTA4-4 [97]. 
In chondrocytes isolated from OA cartilage HNE, directly and indirectly, triggered 
several changes affecting the production and activity of collagen network component Col II. 
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Whereas HNE inhibited the expression of Col II, the HNE-modified collagen was not only 
more susceptible for degradation by MMPs especially MMP-13, but it could also interact with 
chondrocytes to induce inflammatory and catabolic responses. Furthermore, HNE binding to 
Col II can cause multiple abnormalities in both phenotype and function of interacting 
chondrocytes by modulating the expression of adhesion molecules such as intracellular 
adhesion molecule 1 (ICAM-1) and α1β1 integrins indicating a role for the aldehyde in the 
alteration of cell-ECM interaction in OA [125]. HNE can also increase in the activity, protein 
synthesis, and mRNA levels of MMP-13 mainly through the activation of p38 MAPK [67]. 
Furthermore, it was also suggested that a post transcriptional HNE-induced conformational 
change on MMP-13 leads to protein activation without proteolytic cleavage of its pro-domain 
[68]. In addition, HNE is well reported to stimulate the oxidation and subsequent 
fragmentation of collagen. These changes can affect the material properties of collagen fibrils, 
making them less resilient hence more prone to mechanical pressure. Consequently, the 
produced brittle cartilage might induce the initiation of OA [128].  
 
4.5.4. HNE and signaling pathways 
The role of HNE has long been a subject of debate whether the aldehyde has a 
“second toxic messenger” role as first hypothesized by Esterbauer and colleagues [118], or if 
it merely represents a marker of extensive tissue damage. This controversy changed recently 
when HNE was found to be a normal constituent of mammalian tissue membranes. In 
addition, growing evidence supported a role for HNE as a modulator of signal transduction 
and posttranslational modification in both physiological and pathophysiological responses. 
This role of HNE is highly regulated in a time-dose-dependent pattern [128, 132-134].  
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In OA, it was reported that free HNE can induce catabolic and inflammatory 
responses in isolated OA chondrocytes and alter the cellular phenotype of OA osteoblasts 
possibly by the modulation of several signaling pathways both directly and indirectly by 
modifying pathway components [52, 67, 113]. HNE binding to Col II modulates the 
expression of adhesion molecules such as ICAM-1 and α1β1 integrins. Adhesion molecules 
are expressed on cell surface and their interactions with the surrounding environment is 
important for a vast array of biological processes including cell viability, inflammation and 
catabolism. HNE-modified Col II affected the expression of both ICAM-1 and α1β1 integrin 
at the protein and mRNA level [125]. Additionally, HNE-modified Col II could affect multiple 
OA related catabolic and inflammatory responses via the activation of MAPKs and nuclear 
factor-kappa B (NF-κB) [52, 113]. Data obtained suggest that NF-κB/ ERK1/2 and p38 kinase 
oppositely regulated cell viability and adhesion in the presence of HNE-Col II adducts and this 
regulation could be linked to the level of Col II alkylation [125]. A concomitant increase in the 
activity, protein synthesis, and mRNA levels of MMP-13 by HNE occurred at the 
transcriptional level and required the activation of p38 MAPK, but not p54/46 and p44/42 
MAPKs, which is in contrast to the cytokine signaling pathways involved in MMP-13 
synthesis [65-67]. Nevertheless, p38 MAPK is not the sole pathway for HNE signaling [135, 
136]. HNE can also trigger modifications in markers of apoptosis, redox status, and energy 
metabolism in chondrocytes. In HNE-triggered apoptosis, the activity of several classical 
apoptosis markers was highly recognized during HNE-induced chondrocyte death [52]. Fig.4 
illustrates possible scheme for HNE role as modulator of cellular transduction pathways in 
both its free and protein bound forms. Furthermore, different types of cells showed a well 
documented upregulation and activation of pro-apoptotic factors, followed by translocation of 
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certain factors to the nuclease to undergo apoptosis in response to HNE stimulation [137, 138]. 
Focusing on apoptosis signaling pathways in chondrocyte revealed that HNE suppressed pro-
survival Akt kinase activity but, in contrast, induced Fas/CD95 and p53 expression [45, 97]. 
Akt activation is known to lead to the phosphorylation of numerous other proteins involved in 
the regulation of glucose metabolism, cell proliferation, apoptosis, and gene expression [139]. 
The analysis of cellular energy and redox status indicated that HNE induced ATP, NADPH, 
and GSH depletion and inhibited glucose uptake and citric acid cycle activity. Such HNE 
induced changes in factors known to be essential for normal cell activities can exert 
deleterious effects on chondrocytes ultimately inducing apoptosis. Interestingly, while the 
complete loss of HNE-detoxifying enzyme GSTA4-4 in chondrocytes augmented HNE 
cytotoxicity, significant protection against HNE-induced cell cytotoxicity was achieved by 
enzyme overexpression. Therefore, change in GSTA4-4 expression is expected to have an 
impact in HNE-induced apoptosis.  [52, 97]. 
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Figure 4: Possible scheme for HNE role as modulator of cellular signaling pathways in its 
free and protein bound forms. 
 HNE can modulate the transcription of pro-inflammatory and pro-catabolic mediators leading 
to cartilage damage in OA. Adapted from Bentz et al. 2012[85] 
 
5- TRANSCRIPTION FACTOR Nrf2 
 
5.1 Definition and function. 
Since its identification in 1994 [140] the transcription factor named nuclear factor-
erythroid-2-related factor 2 (Nrf2) has been gaining a lot of attention as a master positive 
regulator of the antioxidant response [141]. Nrf2 is a cap'n’collar basic leucine zipper 
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transcription factor that controls the expression of several enzymes by modulating human 
antioxidant response element (ARE). In response to endogenous and exogenous stressors Nrf2 
can bind to and positively regulate the transcription of genes having ARE regulatory 
sequences [142]. Nrf2 transcriptional regulation mainly involves ARE-regulated genes 
essential for homeostasis, detoxification, immune, inflammatory responses, and tissue 
remodeling [143, 144].  
 
5.1.1. Signaling pathway of Nrf2  
Regulation of gene transcription through Nrf2 is achieved through signaling 
pathway that involves interaction with Kelch ECH associating protein 1 (Keap1) and ARE. 
Keap1 is a repressor protein in the cytoplasm that binds to Nrf2 to prevent its translocation to 
the nucleus and promotes its proteasomal degradation. The presence of stress signals triggers 
Nrf2 phosphorylation and dissociation from Keap1 followed by Nrf2 translocation to the 
nucleus. In the nucleus Nrf2 stimulates the transcription of several genes involved in stress 
response such as GST and inhibits cytokine-mediated inflammation [145]. Interestingly, Nrf2 
itself contains an ARE-like sequence in its promoter, hence the transcription factor can 
autoregulate its own expression [146]. Fig.5 illustrates the regulation of gene expression 
through Keap1-Nrf2-ARE pathway. The discovery of Keap1-Nrf2-ARE pathway and insights 
on it at molecular level can be found in detail in dedicated review [142]. 
In fact, the Keap1-Nrf2-ARE pathway is highly regulated and plays a cardinal role 
in cellular homeostasis. Therefore, Nrf2 is being studied for its relevance to disease prevention 
especially with the discovery of natural and synthetic Nrf2 activators such as, 6-Gingerol and 
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Nrf2 activator II (AI-1), respectively. The use of specific Nrf2 activators provides a precious 
path for enhancing the expression of cytoptotective genes [147, 148].  
 
Figure 5: General scheme depicts the regulation of gene expression through Keap1-Nrf2-
ARE signaling pathway  [142]. 
 
5.1.2. The pathophysiological role of Nrf2 
Oxidative stress and loss of balance between oxidants and antioxidant protection 
within the cell are proposed as important factors associated with ageing and many pathological 
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conditions [149]. The increased production of pro-inflammatory cytokines such as IL-1β, 
chemokines, MMPs, COX-2, iNOS is a hallmark in the pathology of inflammatory diseases. 
However, the continuous cycle of oxidative stress and overproduction of inflammatory 
mediators can be stopped by the activation of Nrf2/ARE system. The activation of Nrf2 
induces the expression of antioxidant molecules thus negatively regulates the production of 
pro-inflammatory mediators and enzymes [92, 149]. The role Nrf2 and the effect of losing its 
effect in various inflammation-associated disorders such as OA has been reported by several 
studies and discussed in literature review [92]. Recent studies have indicated that constitutive 
Nrf2 activation improves cell survival by enhancing resistance to oxidative stress possibly by 
enhancing the expression of cytoprotective genes such as GSTA4-4 [142]. However, loss or 
disturbance in Nrf2 level and/or activity can strongly affect cellular defense against ROS and 
LPO-products such as HNE [147]. Accordingly, the use of Nrf2 activators to enhance the 
transcription factor activity are considered a promising approach to help the cell eliminate the 
effect of oxidative stress, ROS and their products such as HNE [150] .  
In OA, studies have demonstrated the role of HNE in disease pathogenesis. Ageing, 
an important risk factor for OA, is also associated with decline in Nrf2 expression leading to 
impairment in the expression of cytoprotective molecules [151].   
 
5.1.3 Activators of Nrf2 
Several natural and synthetic compounds are being investigated and/or developed in 
an attempt to regulate and enhance the transcriptional activity of Nrf2. Though its activation 
occurs mainly by triggering the release of Nrf2 from Keap1, several scenarios have been 
described. While the phosphorylation of Nrf2 at serine 40 appears to be an important event in 
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both release from Keap1 and translocation of Nrf2 to the nucleus, kinase signaling pathways 
may be involved, and adduct formation with Keap1 can also take place [152]. The anticipated 
subsequent increase in the expression of cytoprotective molecules makes such activators of 
great benefit especially in inflammatory disorders. Nevertheless, finding a specific Nrf2 
activator that is pharmacologically effective for a specific disorder is still a great struggle [92]. 
Protandim® is a commercial dietary supplement composed of five phytochemicals with 
antioxidant properties. The mixture of these natural Nrf2 activators enhances the expression of 
endogenous antioxidant enzymes through multiple kinase pathways [153]. Moreover, dietary 
administration of Protandim® showed chemopreventive effect on the cell and reduced markers 
of oxidative stress, LPO and subsequently production of HNE in-vitro and in-vivo animal 
models [92, 154]. 6-Gingerol was also reported to be a potent activator of Nrf2. Lee et al. 
[155] have reported that 6-Gingerol exhibits preventive and/or therapeutic potential for the 
management of Alzheimer’s disease via augmentation of antioxidant capacity and Nrf2 
transactivation. Fig.6 lists some of natural Nrf2 activators. 
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Figure 6: Some reported Nrf2 activators in natural dietary supplements. 
 
5.2. Transcription regulation of HNE-detoxifying GSTA4-4 by Nrf2 
GSTs are part of an important cellular response against intrinsic and extrinsic 
cellular stressors. The enzyme facilitates the addition of the antioxidant GSH to electrophiles 
such as HNE for detoxification and to prevent their interaction with cellular components. The 
expression of both inducible and constitutive forms of GSTs is controlled by Nrf2 activity 
[145]. Loss or disturbance in Nrf2 activity greatly affects the inducible expression of GSTs 
and leaves the cell more vulnerable to oxidative stress [142]. GSTA4-4 isoform plays an 
important role in HNE detoxification and in protecting the cell from HNE-induced apoptosis 
[97, 127]. Interestingly, HNE can trigger Nrf2 release from Keap1 ultimately inducing the 
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expression of GSTA4-4 through Nrf2-ARE activity. This cellular adaptive mechanism is 
programmed to counteract the accumulation of HNE. Upon activation, transcription factor 
Nrf2 can indirectly inhibit HNE production and subsequently the effect of free HNE on signal 
transduction pathways in OA chondrocytes through stimulating GSTA4-4 gene transcription. 
However, the protective antioxidant system within the cell can be overwhelmed by increased 
HNE production in the presence of oxidative stress leading to detrimental effects on the cell 
[156]. Fig.7 represents the proposed role of Nrf2 in the transcriptional regulation of GSTA4-4 
and subsequently in regulating HNE level. 
 
 
Figure 7: A scheme represents the proposed role of Nrf2 activation in regulating HNE 
level. (Adapted from Abusarah  et al. 2012) [157] 
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6. OBJECTIVES AND HYPOTHESIS 
 
It is well demonstrated in the literature that oxidative stress contributes in the 
pathogenesis of OA by causing the accumulation of ROS. Within different tissues the effect of 
ROS might be attributed in part to the production of toxic aldehydes, such as HNE, through 
LPO. Therefore, mechanisms targeting the role of HNE in the disease would be a beneficial 
approach in the treatment of OA. Previously obtained preliminary data indicated interesting 
findings that the expression of both transcription factor Nrf2 and GSTA4-4, is dramatically 
decreased in human OA cartilage as compared with control. This observation prompted further 
investigation regarding the significance of decreased GSTA4-4 and Nrf2 in cartilage. The 
current study focuses on the role of Nrf2 as a key transcription factor for multiple cellular 
stress-response genes such as phase-2 detoxifying enzyme GSTA4-4 which plays an important 
role as HNE detoxifying enzyme. Protandim®, a commercial product composed of a mixture 
of natural antioxidants is reported to activate and increase the levels of Nrf2 in different 
tissues. The activation of Nrf2 by Protandim® can prevent the production of HNE along with 
the pro-inflammatory and catabolic factors implicated in cartilage degradation in OA, mainly 
by stimulating the expression of GSTA4-4. The concept of activating cellular protection 
against the effect of HNE using Nrf2 as endogenous cellular defence switch can provide a 
promising technique in preventing further HNE-associated cartilage degradation and disease 
progression.  
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CHAPTER II: MATERIALS AND METHODS 
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2.1 Specimen Selection 
Human OA articular cartilage was obtained from OA patients aged (67 ± 9 years, 
mean ± SD) who underwent total knee arthroplasty.  All specimens were collected within the 
first 24 hours post-surgery. Informed consent had been obtained from OA patients for the use 
of their tissues for research purposes. All patients were evaluated by rheumatologists 
according to the criteria set by the American College of Rheumatology [158]. The 
experimental protocol and use of human tissues were approved by the Research Ethics Board 
of Hôpital du Sacré-Coeur de Montréal. 
 
2.2 Sample Preparation and Isolation of Chondrocytes 
OA knee cartilage was aseptically obtained from each specimen, spliced and rinsed to 
prepare the cartilage for the extraction of chondrocytes by sequential enzymatic digestion as 
described previously [159]. OA cartilage was digested with 1 mg/ml of pronase (Sigma, 
Oakville, Ontario, Canada) for 1 hour at 37ºC , followed by 0.5 mg/ml of type IV collagenase 
(Sigma) for 6 hours in Dulbecco’s modified Eagle’s medium (DMEM; Gibco BRL, 
Burlington, Ontario, Canada) supplemented with 10% heat-inactivated fetal bovine serum 
(FBS; Invitrogen Life Technology, Inc., Grand Island, NY, USA), 100 units/ml of penicillin 
and 100 μg/ml of streptomycin (Invitrogen Life Technology, Inc.). The cells were seeded at 
high density in culture flasks at 37ºC in a humidified atmosphere of 5% CO2/95% air until 
they were confluent. 
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2.3 Cell Culture 
When cells were confluent they were seeded (at 105 cells/cm2) in tissue culture plates 
and incubated for 48 hours before treatment. To preserve the phenotype of the cells only 
chondrocytes from first-passage are used. The experiments were performed in DMEM 
containing 1% FBS and antibiotics with the factors under study. Chondrocytes were pre-
treated with different concentrations of, Protandim® (LifeVantage Canada LTD), 6-Gingerol 
(Sigma-Aldrich), or AI-1 (Calbiochem) for one hour. Then cells were treated either with IL-1β 
(1 ng/ml) or with H2O2 (500 mM/ml) for 24 hours.  
 
2.4 Protein Detection by Western Blotting 
20 micrograms of total proteins from chondrocyte lysates under the indicated 
conditions were loaded for discontinuous 4-12% sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE). They were then transferred electrophoretically onto 
nitrocellulose membranes (Bio-Rad Laboratories, Mississauga, ON, Canada) for protein 
immunodetection, and semi-quantitative measurement as described previously [159]. 
The primary antibodies were: rabbit anti-human Nrf2 (R&D Systems); rabbit anti-
human Gsta4-4 (Abcam Inc); mouse anti-b-actin (Sigma-Aldrich). After serial washes, 
primary antibodies were detected by anti-mouse or anti-rabbit IgG conjugated to horseradish 
peroxidase (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, USA).  
Immunoreactive proteins were detected with SuperSignal blotting substrate (Pierce 
Biotechnology, Inc., Rockford, IL, USA) and exposed to half-blue x-ray film (Bioflex, 
Clonex, Interscience)  
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2.5 MMP-13 Assay 
Active MMP-13 enzyme was quantified in conditioned medium using Human pro-
MMP-13 Immunoassay enzyme-linked immunosorbent assay (ELISA) kit (R&D Systems, 
Minneapolis, MN, USA) according to the manufacturer’s instructions.  The sensitivity of the 
kit is 8 pg/ml. Assay was performed in duplicates. Absorbance was measured using the micro-
ELISA Vmax photometer (Bio-Tek Instruments, Winooski, VT, USA). 
 
2.6 PGE2 Assay 
PGE2 level was assessed in conditioned medium by enzyme immunoassay (Cayman 
Chemical Company) according to the manufacturer’s instructions. Detection sensitivity of the 
kit is 9 pg/ml. The assay was performed in duplicates. Absorbance was measured with the 
micro-ELISA Vmax photometer (Bio-Tek Instruments, Winooski, VT, USA). 
 
2.7 NO Assay 
Nitrite, a stable end-product of NO, was quantified in the supernatant according to a 
spectrophotometric method based on Griess reaction [160]. Assay was performed in 
duplicates. Absorbance was measured with the micro-ELISA Vmax photometer (Bio-Tek 
Instruments, Winooski, VT, USA). 
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2.8 Viability test  
Chondrocyte viability was evaluated using 3-(4,5-dimethyl-thiazoyl)-2,5-diphenyl-SH-
tetrazolium bromide (MTT) assay in 96-well plates (Fisher Scientific Company, Ottawa, ON, 
Canada) as described previously [161]. Cells were incubated with 0.5 mg/ml MTT reagent 
(Sigma-Aldrich) for 15 minutes at 37ºC, and then 100 μL of solubilization solution (0.04 M 
HCl-isopropanol) was added to dissolve the formed formazan salt. Absorbance was measured 
at 570 nm with the micro-ELISA Vmax photometer (Bio-Tek Instruments, Winooski, VT, 
USA). 
 
2.9 Cartilage homogenization 
Cartilage explants (~50 mg) were homogenized on ice in 1 ml of 
radioimmunoprecipitation assay (RIPA) buffer (150 mM NaCl, 1 mM EDTA, 40 mM Tris, pH 
7.6, 1% Triton X-100), supplemented with protease inhibitors and 2 M guanidine 
hydrochloride. Extracts were dialyzed overnight against RIPA buffer at 4°C and conserved at  
-80°C.  
 
2.10 RNA extraction and reverse transcription-polymerase chain reaction (RT-PCR)  
Total RNA was isolated with TRIzol reagent according to the manufacturer's 
instructions (Invitrogen). RNA was quantitated with RiboGreen RNA quantitation kits 
(Molecular Probes, Eugene, OR, USA), dissolved in diethylpyrocarbonate-treated H2O, and 
stored at -80°C until used. 1 μg of total RNA was reverse-transcribed with Moloney murine 
leukemia virus reverse transcriptase (Fermentas, Burlington, Ontario, Canada), as detailed in 
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the manufacturer's guidelines. One-fiftieth of the reverse transcriptase reaction product was 
analyzed by real-time quantitative PCR. The following specific sense and antisense primers 
were purchased from Bio-Corp Inc. (Montreal, QC, Canada): mouse Gsta4-4, 5 -GGA AGA 
ACT CAG TGC CCC TGT AC-3’ (forward) and 5 - TGT AGG AAT GTT GCT GAT TCT 
TGT C-3’ (reverse); Nrf2, 5′- AGC AGG ACA TGG AGC AAG TT-3’ (forward) and 5′- TTC 
TTT TTC CAG CGA GG AGA-3’ (reverse); mouse GAPDH, 5′- TGG AAT CCT GTG GCA 
TCC ATG-3′ (forward) and 5′- TAA AAC GCA GCT CAG TAA CAG TC-3′ (reverse).  
Quantitative PCR analysis was performed in a total volume of 50 µl containing 
template DNA, 200 nM sense and antisense primers, 25 µl of SYBR Green Master Mix 
(Qiagen, Mississauga, Ontario, Canada), and 0.5 units of uracil-N-glycosylase (UNG, 
Epicentre Technologies, Madison, WI, USA). After incubation at 50°C for 2 minutes (UNG 
reaction) and at 95°C for 10 minutes (UNG inactivation and activation of AmpliTaq Gold 
enzyme), the mixtures were subjected to 40 amplification cycles (15 s at 95°C for denaturation 
and 1 minute at 60°C for annealing and extension). Incorporation of SYBR Green dye into the 
PCR products was monitored in real-time with a Mx3000 real-time PCR system (Stratagen, La 
Jolla, CA, USA), allowing determination of the threshold cycle (Ct) at which exponential 
amplification of PCR products begins. After PCR, dissociation curves were generated with 1 
peak, indicating amplification specificity. A Ct value was obtained from each amplification 
curve with software provided by the manufacturer (Stratagen). 
Relative mRNA expression in chondrocytes was quantified according to the ΔΔCt 
method, as detailed in the manufacturer's (Stratagen’s) guidelines. A ΔCt value was calculated, 
first by subtracting the Ct value for the housekeeping gene GAPDH from the Ct value for each 
sample. A ΔΔCt value was then calculated by subtracting the ΔCt value for the control 
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(unstimulated cells) from the ΔCt value for each treatment. Fold changes compared to the 
controls were then determined by 2-ΔΔCt. Each PCR generated only the expected specific 
amplicon, as shown by melting temperature profiles of the final product and by gel 
electrophoresis of the test PCRs. Each PCR was run in triplicate on 2 separate occasions for 
each independent experiment (n=3-4). 
 
2.11 Surgically induced OA mouse model.  
OA was surgically induced in 10-week-old male 129S6/SvEv mice by destabilization 
of the medial meniscus (DMM) in the right knee, as previously described [162]. The mice 
were anesthetized with isoflurane and O2, and the right knee joint was destabilized by 
transection of the anterior attachment of the medial meniscus to the tibial plateau. A sham 
operation, which involved a similar incision to the knee without compromising the joint 
capsule, was also performed on the right knee of 10-week-old 129S6/SvEv mice. Animals 
with DMM received intraarticular injection (10 mL) of saline solution (0.9 g/L NaCl) or 
Protandim® at 1 mg/ml. Mice were observed daily to verify healing and to ensure that they 
were using their right limb. The description of animal groups were reported in table  
Groups 10-weeks old 
Group 1: Sham 
Group 2: OA 
Group 3: OA + Protandim  
N=3 
N=4 
N=4 
Table 1: Description of different groups of Sham, OA, and OA + Protandim® mice. 
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2.12 Cartilage histology 
Operated mice (sham and OA mice) were euthanized at 12 weeks after surgery. To 
assess OA severity, we evaluated isolated knee joints histomorphometrically. The right knee 
joints were dissected free of skin tissue, fixed in TissuFix (Chaptec), decalcified in RDO 
Rapid Decalcifier (Apex Engineering), and embedded in paraffin, as previously described 
[163]. Briefly, frontal histological sections (5 µM) were obtained throughout the knee joint at 
80 µM intervals, deparaffinised in xylene, followed by a graded series of alcohol washes, 
stained with Safranin O–fast green (Sigma-Aldrich), and scored by 2 blinded observers 
according to the OARSI mouse scoring system [164], which grades cartilage structure and PG 
content on a scale of 0-6 (where 0 = normal cartilage, 0.5 = loss of PGs without structural 
changes, 1 = superficial fibrillation without structural changes, 2 = vertical clefts and loss of 
surface lamina, 3 = vertical clefts/erosion of the calcified layer lesion for 1-25% of quadrant 
width, 4 = lesion reaches calcified cartilage for 25-50% of quadrant width, 5 = lesion reaches 
calcified cartilage for 50-75% of articular surface, and 6 = lesion reaches calcified cartilage for 
>75% of quadrant width). All joint quadrants (medial tibial plateau, medial femoral condyle, 
lateral tibial plateau, and lateral femoral condyle) were scored separately, and the scores were 
added to obtain summed OA scores for the whole joint.  
 
2.13 Plasmids and transient Nrf2 transfection 
Wild type and mutant GSTA4-4 expression plasmids were generously gifted by Dr. S. 
Awasthi [126] (University of North Texas Health Science Center, Fort Worth, TX, USA). The 
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expression vector of Nrf2 is gifted by Dr. Yue Xiong (University of North Carolina, 
Lineburger Cancer Center, NC, USA). Subconfluent chondrocytes were transiently transfected 
by Lipofectamine 2000TM reagent (Invitrogen Life Technology) according to the 
manufacturer’s protocol. Briefly, transfections were conducted for 6 hours with DNA 
lipofectamine complexes containing 10 µl of lipofectamine reagent, 2 µg empty DNA 
plasmid, 2 mg Nrf2 expression plasmid, and 0.5 µg of pCMV-β-gal (as a control of 
transfection efficiency). After washing, experiments were performed in 2% FBS fresh medium 
supplemented or not with 1 ng/ml IL-1β. Then, Nrf2 expression was analyzed by Western 
blotting, as described previously. β-gal level was measured with ELISA kits from Roche 
Diagnostics Canada, Laval, QC, Canada). 
 
2.14 Cellular level of HNE-protein adducts 
Total cellular levels of HNE-protein adducts were assessed by enzyme-linked 
immunosorbent assay, as described by Benderdour et al. 2003 [128] with some modifications. 
To prepare the HNE-BSA standard, BSA (Sigma) was dissolved in 50 mM phosphate-
buffered saline (PBS; 5 mg BSA/ml), pH 7.2, and incubated at 37°C for 1 hour in the presence 
of 0.1 mM HNE. The HNE-BSA solution was then filtered and washed four times with PBS 
using 10,000 MWCO centrifugal filters (Millipore). Immulon II microtiter plates (VWR 
International) were precoated overnight at 4 °C with 100 μl of HNE-BSA standard or sample 
(tissue protein extracts concentrated 5-fold), washed four times with PBS, and then incubated 
with 200 μl of blocking buffer (5% BSA and 5% fetal bovine serum) for 4 hours at room 
temperature. The blocking buffer was discarded, and the plates were incubated overnight at 
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4°C with 200 μl of primary antibody rabbit anti-HNE (1:1,000 dilution in 0.05% Tween-PBS). 
After washing four times with Tween-PBS, 200 μl of the goat anti-rabbit IgG-horseradish 
peroxidase conjugate (1:50,000; The Jackson Laboratory) were added, and the plates were 
incubated for 2 hours at room temperature. Detection was carried out with a Sigma Fast™ 
POD kit (Sigma). After a 10 to 20 min incubation at room temperature, the reaction was 
stopped with 50 μl of 2N H2SO4, and absorbance at 450 nm was measured with a microplate 
reader. A linear response in the range up to 5 μg/ml of HNE-modified BSA standard was 
observed (slope = 0.30 ± 0.03; coefficient of correlation = 0.99; p < 0.0001). 
 
2.15 Statistical Analyses 
Results were expressed as the mean ± standard error of the mean of eight specimens, 
and assays were performed in 3 independent experiments. Statistical analysis was performed 
using the two-tailed paired Student t test, and a difference of less than or equal to 0.05 was 
considered significant. 
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1- Natural and synthetic Nrf2 activators safely increase Nrf2 protein level  
To evaluate the effect of Nrf2 activation samples were treated with two natural and one 
synthetic activators of Nrf2; Protandim®, 6-Gingerol and Nrf2 activator II (AI-1), 
respectively.  Chondrocytes were first treated with three different Nrf2 activators at increasing 
concentrations for 24 hours. Cell viability is then determined using MTT test and calculated as 
percentage of control. Obtained results depicted in figure 8A show no change in cell viability 
with Protandim® and 6-Gingerol at tested concentrations. Synthetic activator AI-1 however, 
shows some toxicity at concentration ≥10 µM. The level of total Nrf2 protein was then 
assessed in cellular extracts using Western blot. Figures 8B shows visible dose-dependent 
increase in total Nrf2 with Protandim®. However, it is well reported in the literature that 
Protandim® can activate Nrf2 in different cell lines by inducing the latter’s nuclear 
localization. This activation is proposed to take place via the activation of various kinases, 
subsequently prompting the phosphorylation of Nrf2 [147, 153]. Therefore, we are 
anticipating that the reported increase in Nrf2 activity is associated with simultaneous increase 
in the level of Nrf2 phosphorylation.  Collectively, our obtained findings confirmed both 
safety and Nrf2 activation capability of Protandim®, AI-1 or 6-Gingerol at concentrations (0-
10 µg, 0-5 µM and 0-10 µM respectively). 
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 Figure 8: Effect of Nrf2 activators on cell viability and Nrf2 expression. 
Human OA chondrocytes were incubated with natural (Protandim® and 6-Gingerol) or 
synthetic activator of Nrf2 (AI-1) at different concentrations for 24 hours. A) Cell viability 
was evaluated using 3-(4,5-dimethyl-thiazoyl)-2,5-diphenyl-SH-tetrazolium bromide (MTT) 
assay in 96-well plates by incubating them with 0.5 mg/ml MTT reagent for 15 min at 37
0
C. 
Then, 100 µL of solubilization solution (0.04 M HCl-isopropanol) was added, formazan salt 
was dissolved, and absorbance was read at 570 nm with the micro-ELISA Vmax photometer. 
(B) Nrf2 total protein expression was determined by Western blot using monoclonal anti-Nrf2 
antibody. Data are the means ± SEM of 4 independent experiments. *P < 0.05, compared to 
untreated cells (1% FBS). 
AI-1 
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 2- Treatment with Nrf2 activators protects chondrocytes against H2O2-induced cell 
death 
It is well reported that H2O2 can induce cell death mainly by increasing oxidative 
stress. However, overexpression of antioxidant molecules and enzymes can protect the cell 
from such outcome [165]. To examine the protective effect of Nrf2 transcription factor against 
oxidative stress-induced cell death, three different Nrf2 activators were tested. First, isolated 
human OA chondrocytes were pre-incubated with increasing concentrations of Nrf2 
activators; Protandim®, 6-Gingerol or AI-1 for one hour. Cells were then treated with 0.5 mM 
H2O2 for 24 hours. Cell viability assay presented in Figure 9 reveals dose-dependent protection 
with all three activators. The maximum activation was obtained with 6-Gingerol at 10 µM 
with 105% when compared to untreated cells. These readings suggest that Nrf2 activation can 
protect the cells from the cytotoxicity of H2O2.  
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Figure 9: The activation of Nrf2 protects the cell against H2O2-induced cell death.  
Human OA chondrocytes were pre-incubated with Protandim®, AI-1 or 6-Gingerol 
(concentrations 0-10 µg, 0-5 µM and 0-10 µM respectively) and then incubated with 0.5mM 
H2O2 for 24 hours. Cell viability was assessed by MTT assay as described in the legend of the 
figure 8. 
 
3- Nrf2 activation inhibits the production of catabolic and inflammatory mediators  
There are number of inflammatory and catabolic mediators implicated in the 
pathogenesis of OA. Increase in the level of PGE2, MMP-13 and NO have been associated 
with disease progression and cartilage damage. Pro-inflammatory cytokine IL-1β has an 
important role in the release of PGE2, MMP-13 and NO by triggering inflammatory and 
catabolic signaling pathways. In OA, samples from articular tissue show persistent increase in 
1 2 3 4 5 6 1 2 3 4 5 6 1 2 3 4 5 6
0
2 5
5 0
7 5
1 0 0
P ro ta n d im A I- I 6 -G in g e ro l
0   0   1   2   5  1 0     1    2   5               1   2   5  10
* *
H 2 O 2  (0 .5  m M )
* *
* *
*
* * *
* *
C
e
ll
 v
ia
b
il
it
y
(%
 o
f 
c
o
n
tr
o
l)
 60 
the level of IL-1β [29]. In this study we tested the influence of Nrf2 activation on the level of 
IL-1β-induced release of PGE2, MMP-13 and NO in isolated human OA chondrocytes. To do 
so, cells were pre-incubated with increasing concentrations of Protandim®, AI-1 or 6-Gingerol 
for one hour followed by stimulation with 1 ng of IL-1β for 24 hours. The concentration of 
PGE2, MMP-13 and NO was then calculated in collected cell culture medium using 
commercial assays. Interestingly, as shown in Figure 10, Nrf2 activators have an inhibitory 
effect on the level of three mediators. The reported effect shows dose dependant response as 
well. At 10 µM, 6-Gingerol showed to be the most potent inhibitor of IL-1β-induced MMP-13, 
NO, and PGE2.  
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Figure 10: Isolated human OA chondrocytes were pre-treated with increasing concentrations 
of three different Nrf2 activators; Protandim®, AI-1 or 6-Gingerol (0-10 µg, 0-5 µM and 0-10 
µM respectively) for one hour. The cells were then treated with 1 ng/ml of IL-1β for 24 hours. 
Cell culture medium was collected and assayed against A) PGE2, B) MMP-13 and C) NO. 
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Values represent the means ± SEM of 4 separate experiments performed in duplicate. *P < 
0.05, **P < 0.01, ***P < 0.001 compared to IL-1β-treated cells. 
 
4- The dietary use of Protandim® in DMM mouse model of OA shows reduced cartilage 
degradation 
To further evaluate the overall protective capability of Nrf2 activation, we tested the 
influence of the dietary consumption of Protandim® in the surgical DMM model of OA. Mice 
were given either vehicle or Protandim® for 8 weeks post-surgery.  After sacrifice, 
histological cartilage samples from the knee were evaluated for signs of cartilage degradation 
such as fibrillation with loss of chondrocytes and loss of aggrecan. Each sample was given a 
score according to OA Research Society International (OARSI) score system. Figure 11 
presents the obtained findings which indicate that oral administration of Protandim® is 
associated with lower OARSI score and much lower cartilage degradation when compared 
with placebo.  
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Figure 11: Protandim®-activating Nrf2 reduces cartilage degradation in DMM mouse 
model of OA.  
Histological section of the medial tibial plateaus and femoral condyles performed in DMM 
wild-type (WT) mice treated with (A) vehicle, (B) 10 mg/kg/day Protandim® for 8-weeks post 
surgery. (C) Sham mice 8-weeks post-surgery. Arrows indicate areas of fibrillation with loss 
of chondrocytes and Safranin-O staining (loss of aggrecan). F indicates femoral condyle and T 
tibial plateau (original magnification X40). Statistics: P values were assessed by Mann-
Whitney U test comparing DMM mice + drug to the DMM mice + vehicle. (n=4).  
C 
Tibial plateau 
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5- Cartilage from human OA patients and mouse model of OA show profound decline in 
the expression of Nrf2 and GSTA4-4  
The transcription factor Nrf2 is an important modulator of transcription for cellular 
antioxidant enzymes. The expression of the important HNE-detoxifying enzyme GSTA4-4 is 
also modulated by Nrf2 transactivation. Loss of the protective role of GSTA4-4 and its 
modulator Nrf2 can leave the cell susceptible to the deleterious effects of HNE and oxidative 
stress [166]. In OA, we postulate that the decrease of Nrf2 and GSAT4-4 may contribute to 
HNE accumulation and consequently to cartilage damage. The objective was to evaluate the 
level of Nrf2 and GSTA4-4 expression in OA cartilage. Figure 12A unveils significant 
decrease in (A) Nrf2 and GSTA4-4 protein level in human OA cartilage samples as compared 
to normal and (B) Nrf2 and GSTA4-4 mRNA levels in cartilage from DMM mouse model of 
OA as compared to sham. Collectively, obtained results reveal an important decline in both 
Nrf2 and GSTA4-4 at both mRNA and protein levels in OA cartilage. 
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 Figure 12: (A) Expression of Nrf2, GSTA4-4 was decreased in human OA cartilage (n = 3-
4). Cartilage extracts from healthy subject and OA patients are subjected to Western blot using 
monoclonal anti-human Nrf2 and GSTA4-4. (B). Nrf2 and GSTA4-4 mRNA levels were 
determined by real-time PCR in cartilage from sham and DMM WT mice 8-weeks post-
surgery. Statistics: Student's unpaired t-test (n=3-4): **P < 0.01 (vs. sham).  
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6- Increased Nrf2 activity reverses the effect of IL-1β on the expression of GSTA4-4, 
MMP-13 and on the production of HNE  
IL-1β plays an important role in OA by triggering the release of catabolic and 
inflammatory mediators as well as oxidative stress markers [30]. In the next series of 
experiments, we investigated whether Nrf2 activation abolishes IL-1β induced MMP-13 and 
HNE production and GSTA4-4 inactivation in human OA chondrocytes. To do so, cells were 
pre-treated with 10 mg/ml Protandim® for 1 hour followed by incubation with 1 ng/ml IL-1β 
for 24 hours. As illustrated in Figure 13, Protandim® restores GSTA4-4 activity (A) and 
blocks IL-1β -induced MMP-13 and HNE production (B, C).  
 
CTL                IL-1β              IL-1β+ 
                                            Protandim 
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Figure 13: The activation of Nrf2 by Protandim® abolished IL-1β -induced GSTA4-4 
down-regulation (A), HNE production (B), and MMP-13 release (C). 
Isolated chondrocytes were pre-incubated for 1 h with 10 g of Protandim® followed by 
incubation for 24 hours in the presence or absence of 1 ng/mL IL-1. GSTA4-4 mRNA 
expression was determined by real-time PCR (A). HNE (B) and MMP-13 (C) levels were 
C 
CTL                IL-1β               IL-1β+ 
                                            Protandim 
CTL              IL-1β             IL-1β+ 
                                        Protandim 
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measured by ELISA in the cellular extracts and culture media, respectively. Statistics: 
Student's unpaired t-test (n=3): **P < 0.01, ***P < 0.01 (vs. CTL); #P<0.05, &P<0.01 (vs. IL-
1). 
 
7- The effect of IL-1β on the levels of Nrf2, GSTA4-4, MMP-13 and HNE can be 
overcome by Nrf2 overexpression  
This experiment is designed to investigate whether Nrf2 overexpression is essential to 
block IL-1β induced GSTA-4-4 down-regulation as well as MMP-13 and HNE production. 
Briefly, human OA chondrocytes were transiently transfected with Nrf2 expression vector or 
empty vectors and then treated or not with 1 ng/ml IL-1β for 24 hours. As shown in figure 
14A (upper panel), IL-1β reduced Nrf2 expression in a dose-dependent manner. Furthermore, 
the overexpression of Nrf2 (Fig. 14A lower panel) significantly abolished IL-1β-induced 
GSTA4-4 down regulation (Fig. 14B), HNE generation (Fig. 14C), and MMP-13 release (Fig. 
14D). Altogether, our data confirm that Nrf2 is essential to regulate redox status and cartilage-
degrading enzymes.  
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Figure 14: (A) IL-1β inhibits Nrf2 expression in human OA chondrocytes. Cells were treated 
with 1 and 2 ng/mL IL-1β for 24 hours. (B-D) Overexpression of Nrf2 (A, lower panel) 
prevented the IL-1β-induced GSTA4-4 down-regulation (B), IL-1β-induced HNE generation 
(C) and MMP-13 (D) release. Isolated chondrocytes were transiently transfected with empty 
or Nrf2 expression vector (1 ng/10
6
 cells) and treated than after for 24 hours with or without 1 
ng/mL IL-1β. Cellular extracts were subjected to the determination of Nrf2 by Western blot (A 
 70 
lower panel), GSTA4-4 mRNA expression by real-time PCR (B), and HNE level by ELISA 
(C). MMP-13 level was measured in the culture media by ELISA (D). Statistics: Student's 
unpaired t-test (n=3): *P < 0.05, **P < 0.01, ***P < 0.001 (vs. empty vector; #P<0.05, 
&P<0.01 (vs. empty vector + IL-1β). 
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CHAPTER IV: DISCUSSION 
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OA is the most common joint disorder that significantly limits physical activity and 
productivity. Its prevalence is expected to increase significantly in the upcoming decades, as a 
result of increased life expectancy and population aging. Consequently, it is of greatest social 
importance that we facilitate advances in the treatment of this musculoskeletal disorder 
through research, the goal of which should be to improve disease prevention and treatment. 
There is currently no effective treatment to prevent or stop cartilage destruction during OA 
and the primary goal is to alleviate pain and other associated symptoms. Therefore, 
identification of agents that down-regulate the expression of cartilage degrading enzymes may 
prove useful for the prevention or treatment of OA. 
Over the past decades, ROS have been at the center of the pathophysiological scene of 
OA disease. Since its inception, this project has evolved along with the research fields of ROS 
and OA. What was striking in the last decades was the discordance between the enormous 
volume of data supporting the involvement of ROS in OA development and the inconclusive 
clinical results of exogenous antioxidants therapy. These results highlight the existence of 
other reactive species that are not taken into account. In this light, our research is focused on 
clarifying the role of a secondary, potentially toxic product, namely, HNE, which is produced 
from ROS-induced LPO. HNE is a signaling mediator with wide-ranging biological effects. 
Initial emphasis was on the development of immunological methods using ELISA in order to 
detect this aldehyde in biological samples. Using this method, we were able to detect and 
quantify protein-bound HNE in synovial fluids and articular tissues from OA patients [67]. 
These measurements represented a major milestone toward the assessment of the functional 
significance of these HNE-protein adducts and provide a reliable marker of ROS-induced LPO 
in tissue. Moreover, our research group has made major advances in understanding how it 
 73 
participates in signal transduction and post-translational modification (PTM) of proteins in OA 
[45, 52, 67, 97, 125]. Recently, we reported that biochemical changes similar to those seen in 
OA were induced with an intra-articular injection of HNE into dog joints, suggesting the direct 
involvement of HNE in OA. In this study, we also showed that HNE injected into dog joints 
resulted in a significant decrease in proteoglycan content and an increase in MMP-13 and 
aggrecanase-2 levels [167]. 
 
HNE in the pathology of OA 
Although oxidative stress is thought to be involved in the pathogenesis of OA, there is 
no conclusive experimental evidence supporting the idea that defective antioxidant responses 
in joints lead to increased cartilage destruction. Oxidative stress has an important role in the 
pathology of several diseases such as OA. In the presence of ROS and pro-inflammatory 
mediators such as H2O2 and IL-1β, respectively, there is an important increase in the 
production of LPO-end products, in particular, the toxic aldehyde HNE [67]. The structure and 
properties of HNE make it a target for close investigation in several labs including ours to 
better understand its unique role as pathophysiological modulator in OA.  
 
Production of HNE in OA articular tissues  
The accumulation of HNE in OA articular tissues were indicated by various reports. 
Recently, we have documented a significant increase in the level of HNE in synovial fluid 
samples from OA patients as compared with those from controls [67]. These data are 
consistent with the results reported by Grigolo et al [168] and Shah et al. [169] who found 
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higher levels of both MDA and HNE in human OA articular tissues as compared with control. 
However, factors promoting increased accumulation of HNE-protein adducts in OA remain to 
be clarified. These factors include the inactivation of antioxidant enzymes, the up-regulation 
of NADPH oxidase, and the regeneration of GSH [103]. In addition, another factor to be 
considered is the intrinsic capacity of cells to metabolize HNE, whether free or bound, to 
nontoxic products. This can occur through conjugation with GSH by the GSTA4-4 followed 
by export [170]. In another study, we demonstrated that GSTA4-4 overexpression in 
chondrocytes offered significant protection against HNE-induced cell cytotoxicity [97]. These 
data support the critical role of this enzyme in OA through its ability to regulate HNE level in 
cartilage.  
 
HNE induces catabolic and inflammatory responses in OA.  
In OA chondrocytes, we reported that HNE inhibits type II collagen (Col II) expression 
[67]. In OA cartilage explants, HNE increases the degradation of Col II, as determined by the 
measurement of Col II fragments and hydroxyproline release. These data could be attributed to 
the spontaneous Col II degradation or to MMPs up-regulation. Indeed, it clearly showed that 
HNE increases the MMP-13 activity and expression, via p38 MAPK activation. On the other 
hand, HNE increased PGE2 release and COX-2 expression in OA chondrocytes [52]. The 
HNE-induced COX-2 production required the activation of p38 MAPK signaling pathway and 
ATF-2 and CREB-1 transcription factors transactivation. These results were supported by 
others studies indicating that HNE is a potent inducer of COX-2 and PGE2 release in various 
cell lines [171, 172]. The upregulation of COX-2 by HNE contrasted with that of inducible 
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nitric oxide synthase (iNOS) expression [52]. HNE reduced dramatically IL-1β-induced NO 
and iNOS production through inactivation of the NF-ĸB pathway. In a recent study, we have 
also demonstrated that HNE depletion in chondrocyte is responsible for the switch from COX-
2 to 5-lipoxygenase pathway [45]. 
 
HNE-induced protein modification in OA  
One major effect of HNE in OA is its ability to form adducts with specific proteins. 
We reported that MMP-13 activity was regulated by HNE binding [67]. The activation of 
MMP-13 by HNE could occur by conformational change without proteolytic cleavage of its 
pro-domain, probably via the cysteine switch mechanism [173]. In addition, we showed an 
increase in HNE-Col II adducts within OA cartilage. The modification of Col II by HNE 
binding increased the vulnerability of HNE-modified Col II degradation by MMP-13. Col II 
has been identified also as a potential target for MDA binding in chondrocytes [169]. These 
results are consistent with the findings of other studies indicating that incubation of 
chondrocytes with calcium ionophore results in the accumulation of oxidized proteins and, in 
turn, in matrix degradation [174]. Squier reported that oxidatively modified proteins are highly 
sensitive to proteolytic breakdown [175]. The fact that HNE increased the proteolytic 
susceptibility of Col II suggests the presence of changes in the structure of the protein. The 
significance of increased HNE-Col II adducts in OA cartilage was recently clarified. We 
showed that interactions between chondrocytes and HNE-Col II adducts, via adhesion 
molecules, strongly evoking a panoply of signaling pathways that trigger cell adhesion and 
viability as well as MMP-13 and COX-2 expression [125], as illustrated in Figure 15.  
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Figure 15: Effect of HNE-modified ECM components on chondrocytes. 
Scheme represents signaling pathway affected by cell interaction with HNE-modified Col 
II in ECM [125] . 
  
Nrf2 and GSTA4-4 in OA 
To manage the level of HNE and other LPO-end products the cell has an antioxidant 
system to keep HNE below pathological concentrations. Mechanisms promoting increased 
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HNE accumulation in OA remain to be clarified. The GSTs are major determinants of 
intracellular HNE concentration and can influence susceptibility to toxic effects, particularly 
when HNE and GST levels are altered in disease states [127]. GSTs comprise a family of 
versatile enzymes that catalyze the nucleophilic conjugation of GSH with HNE [176]. The 
GSTA4-4 isoform is selective for GSH conjugation of LPO products and is well-recognized 
for its catalytic efficiency with HNE [177, 178]. Disruption of this gene enhances HNE tissue 
levels, as verified experimentally in 129/sv GSTA4-4-/- mice [179]. GSTA4-4 null mice have 
a short lifespan, supporting the possible relationship between HNE and aging. 
By forming adducts with the aldehyde, GSTA4-4 helps detoxify free HNE molecules 
and prevent its accumulation and interaction with cellular components. In fact, in a previous 
study we have reported that the overexpression of GSTA4-4 protects chondrocytes from the 
HNE-induced apoptosis [97]. However, when the production of HNE extends the capacity of 
GSTA4-4 for detoxification, the cell becomes susceptible for the toxicity of HNE. 
Transcription factor Nrf2 act as a master redox switch that can trigger the expression of 
several antioxidant agents within the cell in the presence of redox-agents. Therefore, the 
activation of Nrf2 is important for protecting the cell against the accumulation of oxidative 
agents by triggering the expression of antioxidant defense mechanisms [92, 147].  
Nrf2 is a redox-sensitive transcription factor which binds to ARE located in the 
promoter region of genes encoding detoxifying enzymes such as GSTA4-4 and related stress-
responsive proteins [180]. Induction of these enzymes via Nrf2–ARE signaling hence provides 
an effective means for achieving cellular protection against a variety of electrophilic 
molecules [142]. Under the basal resting condition, Nrf2 is sequestered in the cytoplasm by 
the cytoskeleton-associated protein, Keap1[149]. Keap1 functions as a negative regulator of 
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Nrf2 by promoting ubiquitination and proteasomal degradation of Nrf2. When liberated from 
its repressor Keap1, Nrf2 translocates into the nucleus and forms a heterodimer with a small 
Maf (sMaf) protein to binds to ARE localized in the promoter regions. 
In addition to protection against oxidative and electrophilic stresses, recent studies 
have demonstrated that Nrf2 responds to pro-inflammatory stimuli and rescues cells/tissues 
from inflammatory injuries [181]. Other studies showed that Nrf2 also inhibits catabolic 
responses through MMP-9 down-regulation [182]. Nrf2-/- mice develop complex pathogenic 
manifestations, including lupus-like autoimmune syndrome, pulmonary fibrosis [183, 184]. In 
a recent study, the involvement of this nuclear factor in cartilage degradation was reported in 
Nrf2-/- mice [185]. A high level of cytokines, chemokines, adhesion molecules and COX-2 
was observed in these mice than that of wild-type animals [186-188]. In contrast, all these 
inflammatory mediators are suppressed by Nrf2 activation and/or overexpression, suggesting 
an anti-inflammatory role of Nrf2. From these data, we believe that changes of Nrf2 
expression could be significantly relevant in OA pathogenesis, contributing to the regulation 
of catabolic and inflammatory mediators.  
In addition, Nrf2-/- mice showed greater activation of NF-κB than in their wild-type 
counterparts [187]. Moreover, the activation of Nrf2 has been shown to directly modify the 
DNA binding domain of NF-kB and AP-1, thereby inactivating these transcription factors 
[189-191]. On the other hand, major systems that orchestrate Nrf2 inactivation involve 
different signaling pathways, including p38 MAPK, ERK, NF-kB and Src kinases [192-195]. 
Interestingly, data from our current study indicates a profound reduction in both Nrf2 
and GSTA4-4 at protein and mRNA level in human OA and animal model of OA samples 
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when compared with control. These findings led us to hypothesize that loss of Nrf2 in articular 
cartilage would induce a reduction in GSTA4-4 expression and activity and consequently 
contribute to induce an oxidative-stress phenotype in chondrocytes. Until now, the role of 
Nrf2 and GSTA4-4 in OA was not yet reported. Moreover, the role of Nrf2 in RA is still 
controversial. On one hand, several studies recorded a protective effect against joint 
inflammation associated with the administration of Nrf2 activators such as Rebamipide and 
the activation of Nrf2 antioxidant pathway [196]. This observation indicates a loss or 
deficiency in Nrf2 activity .On the other hand, Wruck et al. reported an increase in Nrf2, 
which occurs in response to oxidative stress within RA joints. However, they indicate that this 
increase is insufficient to fully counteract the progression of the disease [185]. They 
hypothesize, however, that a deficiency in the Nrf2-mediated antioxidant defenses plays a 
central role in the pathogenesis of RA. Nrf2 deficiency significantly enhanced the severity of 
arthritis in their RA model. The difference between Nrf2-knockout mice and Nrf2-wild-type 
mice with regard to the level of joint destruction was clear on histological sections stained 
with H&E and safranin-O. The evaluation of hyperplasia, pannus formation, erosion of 
cartilage and infiltration in the joint showed a significantly higher rate of destruction in all 
four categories in the Nrf2-knockout mice compared with wild-type mice. We hypothesize 
that an increased oxidative burden resulting from defective oxidative defense may lead to the 
increase in cartilage destruction in arthritic Nrf2-knockout mice. In another study with regard 
to RA, Maicas et al [197] showed that Nrf2 deficiency accelerated the incidence of arthritis, 
and animals showed a widespread disease affecting both front and hind paws. Therefore, the 
inflammatory response was enhanced, with increased migration of leukocytes and joint 
destruction in front paws. They observed an increased production of TNF-α, IL-6, and 
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chemokine (C-X-C motif) ligand 1 (CXCL-1) in the joint, with small changes in eicosanoid 
levels. Serum levels of CXCL-1 and receptor activator for nuclear factor κB ligand were 
enhanced and osteocalcin decreased in arthritic Nrf2-/- mice. The expression of COX-2, 
inducible nitric oxide synthase, and peroxynitrite in the joints was higher in Nrf2 deficiency, 
whereas heme oxygenase-1 was downregulated. Where OA is a degenerative disease, RA on 
the other hand is a systemic one. Though both diseases have different pathologies, they share 
the presence of high level of inflammation. Overall, published studies indicate an important 
role of Nrf2 antioxidant activity in inflammation process and inflammatory diseases.  
 
Nrf2 activators 
Since the identification of its role in the activation of antioxidant gene transcription, 
researches have been looking at transcription factor Nrf2 as an important redox switch in the 
biological system. Moreover, changes in the level of Nrf2  and/or its activity is under 
investigation for a potential role in the pathology of several diseases especially of 
inflammatory nature [149]. In an attempt to control and modulate the activity of Nrf2, which 
can be of great benefit in protecting cells against oxidative stress, several natural and synthetic 
compounds are being studied and developed.  In our study we are testing two natural and one 
synthetic activators of Nrf2; Protandim®, 6-Gingerol and AI-1, respectively. Our results 
indicate that pre-treating cells with Nrf2 activator was associated with an interesting increase 
in total Nrf2 protein level. Moreover, the use of Nrf2 activator not only enhanced both mRNA 
and protein levels of GSTA4-4, but it also prevented the inhibitory effect of IL-1β on the 
expression of GSTA4-4. In addition, pre-treatment with Protandim® significantly reduced IL-
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1β-induced production of HNE within the cell. Interestingly, the increase in Nrf2 and GSTA4-
4 within the cell was accompanied with marked reduction in the levels of inflammatory and 
catabolic mediators; PGE2, MMP-13 and NO in the presence of pro-inflammatory cytokine 
IL-1β. This decrease is most likely due to the lower HNE production. Another test performed 
on histological section of the medial tibial plateaus and femoral condyles performed in DMM 
mouse model of OA provided histological evidence that the administration of 10 mg/kg/day of 
Protandim® for 8 weeks post-surgery significantly protected the cartilage from degradation. 
This finding indicates an important possibility to benefit from early treatment with Nrf2 
activators as a protective approach in people with high risk of developing OA after knee 
surgery.  
In a recent study, we tested our hypothesis that carnosine, an HNE trapping compound, 
prevents cartilage damage [167]. Carnosine has recently attracted much attention as a naturally 
occurring antioxidant agent. We demonstrate that carnosine, given as prophylactic or in pre-
existing OA, is able to reduce cartilage damage most likely through its distinctive combination 
of antioxidant properties. These findings may suggest the involvement of HNE in OA process. 
In keeping with the findings of our study, several recent studies have indicated that carnosine 
abolishes the generation of HNE and other oxidative stress-related products [198, 199]. HNE 
is of particular interest because of its high chemical reactivity, evidenced by its production of 
such varied biological effects [200]. The chemical characteristics of this aldehyde revealed 
that it can also react with reduced GSH at much higher rates that are further accelerated by 
GSTA4-4 [127, 201]. Indeed, its reaction with carnosine may be a second line of defense 
under conditions of GSH depletion. The fact that the administration of exogenous carnosine 
prevents HNE production as well as inflammatory and catabolic factors suggests that despite 
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its slow reactivity, carnosine offers significant protection against HNE toxicity and its 
biological effects, even in GSH-depleted cells and tissues. Furthermore, the oral intake of 
carnosine reduces MMP-13, ADAMTS-5, and COX-2 expression in cartilage and synovium 
explants from the anterior cruciate ligament transection (ACLT) dog model of OA. Our 
observations revealed that carnosine can reduce the initiation and progression of OA structural 
changes by removing HNE from the knee joint and attenuating the expression of factors 
known to be involved in cartilage degradation. These findings imply that HNE is a significant 
contributor to OA cartilage degradation 
 
Regulation of Nrf2 and GSTA4-4 function by acetylation 
At posttranslational level, it has been reported that Nrf2 transactivation and GSTA4-4 
activity are regulated by a process namely acetylation. This process is an important 
posttranslational regulatory mechanism involved in regulating enzyme activity and controlling 
different cellular functions such as protein stability, protein localization, cell viability and 
metabolism [202, 203].  In our unpublished data, we identified two distinct mechanisms 
involved in GSTA4-4 regulation at transcriptional and PTM levels in isolated human OA 
chondrocytes: One involving the suppression of Nrf2 transactivation by acetylation, and one 
involving inhibition of GSTA4-4 activity by acetylation, most likely via down-regulation of 
Sirt2-mediated deacetylation, a member of a deacetylase family of enzymes that has seven 
mammalian homologues. In particular, Sirt1 and Sirt2 hold special importance due to their 
presence in the nucleus and the cytoplasm where they can affect coregulators, enzymes and 
transcription factors involved in gene expression. The activity of Sirt is thought to be involved 
directly and indirectly with certain pathological conditions such as cancer, atherosclerosis and 
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cardiovascular diseases [204, 205]. In OA, recent studies revealed that disease development is 
associated with a decrease in Sirt1 expression which may cause chondrocytes death and the 
loss of ECM [206].  However, the role of acetylation in the regulation of Nrf2 stability and 
transcriptional activity is still controversial. A study by Kawai et al. [207] proposed an 
important role for acetylation in the regulation of location and transcriptional activity of Nrf2. 
The study proposed that Nrf2 undergoes acetylation in the nucleus which enhances its binding 
to ARE and subsequently gene transcription and that the deacetylation of Nrf2 by Sirt1 will 
trigger its release from ARE and relocalization to the cytoplasm, thereby terminating Nrf2-
dependant gene transcription [207]. On the other hand, another study by Mercado et al. [208] 
proposed that increase in Nrf2 acetylation causes reduced Nrf2 stability ultimately impairing 
the transcription of antioxidant genes by Nrf2 and cellular antioxidant defense mechanism in 
the presence of oxidative stress [208]. 
Due to the importance of the reported disturbance in the level of Nrf2 and GSTA4-4, 
better understanding of the possible mechanism causing this reduction and the factors involved 
can provide important insights on OA. Moreover, factors that can modulate the activity of 
Nrf2 and GSTA4-4 may also indirectly regulate the level of HNE within articular tissue and 
therefore serve as a potentially important target in OA.  
 
 
  
84 
 
 CONCLUSION 
 
Our observations revealed promising Nrf2 activators outcomes in the prevention of OA 
cartilage lesions induced by joint instability. Nrf2 activators treatment seems to impact 
oxidative stress and the catabolic and inflammatory pathways of OA by activating GSTA4-4 
and inhibiting HNE production. We strongly believed that we are on the brink of uncovering a 
key aspect underlying the role of HNE in OA onset and the fundamental aspects involved in 
its pathogenesis. In any case, this research project will more directly assess the role of HNE 
and its detoxifying enzyme, GSTA4-4, in OA etiopathogenesis. As well, this study results in 
an increased understanding of the biochemical and molecular mechanisms associated with 
decline of GSTA4-4 as well as Nrf2, an important transcription factor involved in GSTA4-4 
regulation and cell function. Therefore, it is most likely that the future studies will lead to the 
development of the first molecular diagnostic tools for identifying individuals at risk of 
developing of OA. Furthermore, another approach includes developing innovative therapeutic 
approaches to maintain or reactive Nrf2 expression and consequently GSTA4-4 in articular 
cartilage by pharmacological interventions. 
In our study we were able to measure the level of Nrf2 in human OA sample. However, 
we do propose running a large cohort study on patients with OA. Such study can provide solid 
proof for diminished Nrf2 level and/or activity in OA. For future work, we suggest the use of 
DMM mouse model of OA using Nrf2 knockout mice. This can help prove the involvement of 
Nrf2 in OA and the outcomes associated with the loss of its activity on disease development.  
Furthermore, Nrf2 knockout mice can help demonstrate the influence of reduced or 
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diminished Nrf2 level on the concentrations of HNE and GSTA4-4 in articular tissue. We also 
propose the use of canine model of OA; different OA models in dogs are comparable to 
human OA. Moreover, the use of such model permits performing macroscopic examination of 
lesions in OA cartilage, which is not possible with DMM mouse model.  
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